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ABSTRACT

The main purpose of this study was to investigate the possible mechanism(s) ofL
carnitine-mediated modulation of AFB 1 -DNA adducts formation. The first part of the
study investigated the effect of increased doses of carnitine on AFB 1 binding to
macromolecules, AFB 1 uptake, activity of glutathione S-transferase (GST), and total
glutathione concentrations in freshly isolated hepatocytes. Carnitine dose was significantly
correlated with the formation of AFB 1 -DNA adduct ( r = -0.68;p = 0.0002 ), AFB i 
protein adduct (r = 0.58;p = 0.017), but not AFB 1 -RNA adduct (r = 0.14;p = 0.604).
There was no effect of carnitine on the uptake of AFB 1 by the hepatocytes or on the
activity of GST. Carnitine protected AFB 1 -induced reduction of total glutathione
concentration in the hepatocytes, which may contribute to the overall protective effect of
carnitine. The second part of the study investigated the effect of carnitine on the binding
of microsomal-activated AFB 1 to exogenous DNA and protein. Carnitine significantly
decreased the binding of activated AFB 1 to DNA. It is postulated that carnitine reduced
this binding by inhibiting the AFB 1 -epoxide formation and/or binding of AFB 1 -epoxide to
DNA. This effect of carnitine was not very specific because acetylcarnitine and y
aminobutyric acid were equally effective in reducing AFB 1 -DNA adduct formation;
however, choline and glycine had no effect. Carnitine enhanced the binding of AFB 1 as
well as microsomal-activated AFB 1 to rat plasma proteins and bovine serum albumin. This
mode of carnitine actions is proposed to be another mechanism of carnitine-mediated
reduction of AFB 1 -DNA adduct formation.
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CHAPTER 1

Introduction

We have reported earlier that camitine supplementation reduced aflatoxin B1
(AFB 1)-DNA adducts formation in rat liver (Sachan & Yatim 1992). Since AFB1 -DNA
binding is an important step for the carcinogenic effect of AFBi , the attenuation of the
binding by camitine may decrease AFB 1 -induced carcinogenesis. However, the
mechanism by which camitine modulates AFB1 -DNA binding is still unknown. Therefore,
the main focus of this dissertation research is to explore the mechanism(s) for camitine
mediated decrease in AFB1 -DNA adducts formation.
The in vitro experiments will be conducted employing freshly isolated liver cells
(hepatocytes), microsomes, and other biomolecules instead of intact animals. Advantages
of conducting an in vitro experiment are that the experimental conditions can be easily
controlled and, more importantly, that the use of laboratory animals can be minimized.
Furthermore, since the activation of AFB1 is in the rnicrosome and the GSH conjugation is
in the cytosol, experimentation using hepatocytes offers special advantages, such as the
ability to monitor both activation and detoxification pathways of AFB 1 could be monitored
in the same preparation (Metcalfe and Neal 1983). Freshly isolated hepatocytes closely
resembled the in vivo cells and their capacity for AFB1 biotransformation and thus allows
direct monitoring of intracellular DNA adduct production (Bailey et al. 1982). The
concern, however, was whether the carnitine effects found in the intact animals could be
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reproduced in this in vitro system. Therefore, the first objective was to study the effect of
carnitine on the AFB 1 -macromolecule adducts formation in the isolated hepatocytes. The
results of these studies indicated that carnitine incubated in freshly isolated hepatocytes
reduced AFB 1 -DNA binding as we had found in intact animals (Sachan & Yatim 1992).
There are several possible mechanisms for camitine inhibition of the AFB 1 -DNA
formation.Since carnitine has a positively charged�, an electrophilic center, AFB 1 epoxide may bind to camitine as the epoxide binds to DNA at the N7 position of guanine
of DNA. As a result, the DNA may be spared from the electrophilic attack of AFB 1 epoxide.
Carnitine may also influence the activation and/or detoxification processes of
AFB 1 • AFB 1 is first metabolized (Phase I metabolism) by the cytochrome P-450 enzyme
system found in the microsome. This metabolism will produce a variety of metabolites
such as AFB1 -epoxide and hydroxylated metabolites (AFMi , AFP i, AFQi , and
aflatoxicol). AFB 1 -epoxide is a very reactive and unstable metabolite of AFB 1 that will
bind to cellular DNA, RNA, and protein. The effect of camitine on microsomal AFB 1
activation and on the binding of activated AFB 1 (AFB 1 -epoxide) to exogenous DNA will
be investigated.
Carnitine may affect the Phase II biotransformation enzymes that are involved in
detoxification of many xenobiotics and reactive molecules. Glutathione-S-transferase
(GST) is the main enzyme that catalyzes the conjugation of AFB1 -epoxide to glutathione,
resulting in detoxicification of AFB 1 -epoxide. Therefore, the influence of carnitine on
GST activity and total glutathione content in the hepatocyte will be studied.
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We have reported that rats supplemented with camitine had a higher plasma
concentration ofAFB 1 than the unsupplemented animals (Sachan and Yatim 1992).
Therefore, the effects ofcamitine on AFB 1 -protein binding will also be studied.
Also, AFB 1 toxicity and carcinogenicity to cells will not have occurred ifAFB 1
cannot permeate the plasma and nuclear membranes. Therefore, the role ofcarnitine in
the uptake ofAFB 1 by the hepatocytes will be investigated.
It is important to know the specificity ofcarnitine effect since there are a number
ofcarnitine analogs (acylcarnitine) and carnitine-like substances (choline, gamma amino
butyric acid). The carnitine-like substances may also affect AFB 1-DNA adducts
formation and biotransformation ofAFB 1 •
In summary, the questions that this research will address are:
1. Can the modulation ofAFB 1 -DNA adducts formation by camitine in vivo be
duplicated in vitro?
2. What is the effect ofcarnitine on AFB 1 -calfthymus DNA binding mediated
by microsome?
3. What is the effect ofcarnitine on GST activity and total glutathione
concentration?
4. Does carnitine have an effect on cellular uptake ofAFB 1 ?
5. Is the inhibitory effect ofAFB i -DNA binding specific for carnitine?
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CHAPTER2

Review of Literature

Aflatoxins

History
Aflatoxins are a group of mycotoxins produced by the molds Aspergillusflavus
and A. parasiticus. They are commonly found to contaminate food and feeds, such as
milk, corn, peanuts, cottonseed, rice, and barley, grain-fermented beverages and edible
animal tissues (Park & Pohland 1986). The current technology and knowledge can neither
totally inhibit atlatoxins synthesis by the molds nor completely eliminate them once they
are produced. As a result, the significance of aflatoxins contamination has long been
recognized, and limits in agricultural commodities have been set since 1965.
Aflatoxins were first discovered in 1960 when a series of outbreaks in poultry and
fish occurred in different parts of the world. One of the worst outbreaks was the "Turkey
X" disease that caused the deaths of many turkies, ducklings, and chicks in Britain (Blount
196 1). Consumption of atlatoxin-contaminated Brazilian groundnut meal was implicated
in the disease. At the same time, feeding of contaminated corn, peas and cottonseed to
farm animals and fish were reported to cause outbreaks analogous to the "Turkey-X"
disease elsewhere (Palmgren & Ceigler 1983 ).
Experiments conducted on the contaminated Brazilian peanut meal resulted in the
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isolation ofA. flavus, and when the fungus was inoculated into untainted peanut meal, the
fungus produced toxins similar to those found in the contaminated meal (Sargeant 1961).
The isolated toxins were named atlatoxin.
II
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Structure and Toxicity

Aflatoxin B1 (AFB 1), B2 (AFBJ, G 1 (AFG1 ), and G2 (AFGJ are the four main
naturally occurring atlatoxins. The letters B and G refer to the atlatoxins' color under UV
light (B for Blue; G for Green), and the subscripts 1 and 2 refer to their relative positions
on a developed thin-layer chromatography plate. The structure of atlatoxins consists of a
coumarin nucleus attached to a bifuran and either pentanone (AFB1 and AFB2) or a six
membered lactone (AFG1 and AFG2) (Figure 2.1). AFB 1 and AFG1 are more toxic to rats
and ducklings as compared to AFB2 and AFG2 (Wogan et al. 1971). As for
carcinogenicity, AFB1 is more carcinogenic than AFG i , while AFG 1 is more carcinogenic
than AFB2 (Shoenhard et al. 1981).
The metabolites of atlatoxins produced in microbial or animal system include
AFMi , AFM2, AFGMi , AFB:w AFG:w AFP i, AFQi , parasiticol and atlatoxicol. Although
AFM1 is less carcinogenic than AFBi , their toxicities are about similar. AFG2a (also
identified as AFB1 hemiacetal, atlatoxin W and hydroxydihydroatlatoxin) is relatively non
toxic (Palmgren & Ceigler 1983 ). Aflatoxicol is the degradation product of AFB1 and is
very toxic and carcinogenic to trout (Shoenhard et al. 1981). This is because atlatoxicol
can be converted back to AFB1 by reductase and dehydrogenase enzymes (Loveland et al.
1987). However, Gallagher & Eaton (1995) reported that the high rate of AFB1
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biotransformation to aflatoxicol is one reason for Channel catfish being resistant to AFB1
hepatocarcinogenesis. AFP 1 is about 15 times less toxic than AFB 1 (Buehl et al. 1973).

AFB1 Toxicity and Carcinogenicity

AFB1 is the most abundant and toxic form of all naturally occurring aflatoxins. It
is hepatotoxic (O'Brien et al. 1983), hepatocarcinogenic (Adamson et al. 1976), and
teratogenic (Bassir & Adekunle 1970) to various animal species. Rainbow trout (first)
and rat (second) are the two animals most susceptible to the carcinogenic effects of AFB1
as compared to other experimental animals (reviewed by Hendricks 1994). The Channel
catfish is resistant to AFB 1 toxicity and hepatocarcinogenicity mainly because AFB1 is not
rapidly oxidized to form AFB1 -epoxide but instead is rapidly metabolized to aflatoxicol
(Gallager & Eaton 1995). AFB1 represents 75% of all aflatoxins found in contaminated
food and feeds. The main target organs for AFB 1 toxic and carcinogenic effects are the
liver and kidney.
Severe morbidity and deaths attributed to acute toxicity of AFB 1 have been well
documented in laboratory (O'Brien et al. 1983) and farm animals (Palmgren & Ceigler
1983), and humans (Krishnamachari et al. 1975). The AFBi -DNA adducts formation has
a strong correlation to animal and human cancer cases (Thabrew & Bababumi 1980;
Wogan et al. 1971; Alpert et al. 1971; Groopman et al. 1988). The "Vutually Safe Dose"
of AFB1 is estimated at 0.016 ng/kglday (reviewed by Eaton & Gallagher 1994).
Hepatocellular carcinoma (HCC) is a major health problem in China where each
year approximately 110,000 patients are diagnosed with it. The HCC cases in China
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account for almost 45% ofHCC incidences in the world (Parkin et al. 1984). The
mortality rate forHCC is more than 95%. Excluding other risk factors, the consumption
of AFB1-contaminated food such as corn, soya-based products, and peanut oil was
correlated (r = 0.55) to theHCC fatality rates in people living in ten Chinese villages that
were studied. See Yu (1995) for a current review ofHCC in China.

AFB1 Absorption
The absorption of AFB 1 is quite efficient and fast as it has a low molecular weight
and is lipophilic (Hsieh & Wong 1994). AFB 1 is absorbed in the small intestine, and the
duodenum is the most efficient site (Kumagai 1989). Since the absorption is roughly
proportional to AFB 1 concentration, this may indicate a passive absorption of AFB 1 • Once
absorbed, AFB 1 goes into the mesenteric venous blood, into the hepatic portal vein, and
finally into the liver. In an experiment involving ligated small intestines, the absorbed
AFB 1 found in the mesenteric venous blood was in the form of free AFB i, protein bound,
and water-soluble metabolites (Hsieh & Wong 1994). At 65 min post-AFB 1 treatment,
45% of the AFB 1 dose was found in the ligated intestines, and 55% was found in the
whole blood. About 32% of the dose present in the small intestines was bound to protein,
and the rest was as free AFB i , and water-soluble and organic-soluble metabolites (Figure
2.2).

AFB1 Metabolism
Similar to other xenobiotics (foreign substances), AFB1 undergoes phase I and
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phase II biotransformations or metabolisms (reviewed by Eaton et al. 1994). The
metabolism in vivo or in vitro may results in several different derivatives of the mycotoxin.
The liver and kidney are the two main organs where AFB1 is metabolized. In vitro, AFB1
undergoes at least five different types of metabolic reactions with liver enzyme
preparations, which are hydroxylation, hydration, reduction, 0-demethylation, and
epoxidation (Figure 2.3). During the phase I biotransformation, depending on the
pathways, AFB 1 can either be activated or transformed into less toxic compounds. Phase
II pathways involve different transferase enzymes that catalyze the detoxification
(conjugation) reactions of the Phase I metabolites. Species differences, health status,
nutritional manipulations, drugs, and chemicals treatments affect the biotransformations,
and thus, the potency of AFB1 .

Phase I metabolism
AFB1 has to be activated for it to possess toxic and carcinogenic effects. The
phase I biotransformation pathways of AFB 1 with microsomal cytocrome P450 (CYP)
system produced metabolites, such as the reactive AFB1 -8,9-epoxide, the more polar
(hydroxylated) AFM1 and AFQ i , the 0-demethylation AFP i, and the reduced aflatoxicol.
The biotransformation rates of AFB 1 to AFM1, AFP1, and AFQ 1 in human liver slices were
comparable to those found in rat liver slices. Nevertheless, the production of AFB1epoxide and bindings of AFB1 to cellular DNA, RNA, and protein were much lower in
human liver slices than in rat liver samples (Heinonen et al. 1996). The AFB 1 -8,9-epoxide
may covalently bind to cellular DNA and other macromolecules, form AFB 1 -glutathione
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FIGURE 2.3 Metabolism of AFB 1 .
Source: Eaton et al. ( 1 994) Biotransfonnation of aflatoxins. In: The Toxicology of
Aflatoxins: Human Health, Veterinary and Agricultural Significance (Eaton, D. L. &
Groopman, J.D. , eds. ). pp. 45-72. Academic Press, New York, NY.
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conjugate, hydrolyze to form AFB1 -8, 9- dihydrodiol, and/or reduced to a hemiacetal
form. In rats, CYP1A2, CYP2C 1 1, and CYP3A4 isoforms or genes have been found to
activate AFB1 • Whereas in human, CYP1A2, 2A6, 2B7, 3A3 and 3A4 are involved in
AFB 1 -epoxide production (Forrester et al 1990; Eaton & Gallagher 1994; Eaton et al.
1994).
The formation of AFBi -DNA adduct is highly correlated to the carcinogenic effect
of AFB1 in both in vivo and in vitro studies (Dragan & Pitot 1994, ). The major AFB1 DNA adduct formed with liver DNA is atlatoxin B 1 -N7-guanine (AFB1 -N7-gua)
(Essigmann et al. 1977). This adduct is unstable and subjected to decomposition. The
major decomposed derivatives of AFB 1 -N7-gua in rat liver are the imadozole ring-opened
AFB1 formamido-pyrimidine adducts, namely AFB1 -N7-FAPY major and minor (Croy &
Wogan 198 1). AFB 1 -N7-FAPY adducts are more stable, and their accumulation in liver
DNA is related to the subsequent reduction of AFBi -N7-gua adduct level.
AFB1 can also be activated by other reactions not involving cytochrome P450
system. Prostaglandin H synthase (Liu et al. 1990), lipoxygenase (Liu & Massey 1992),
and UV light (Stark et al. 1990) have been shown to activate AFB1 •

Phase n metabolism
The phase I AFB1 metabolites may undergo phase II biotransformation involving
the enzymes glutathione S-transferase (GST), �-glucuronidase, and/or sulfate transferase
which produce conjugates of AFB 1 -glutathione, AFB 1 -glucuronide, and AFB1 -sulfate,
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respectively. The major conjugate of AFB 1 -epoxide identified is the AFB 1-glutathione
conjugate (Monroe & Eaton 1987; O'Brien et al. 1983). This conjugation is the principal
detoxification pathway of activated AFB 1 in many mammals (Figure 2.4). It has been
accepted that cytosolic GST activity is inversely correlated to susceptibility of the several
animal species to AFB 1 carcinogenicity (Eaton & Gallager 1994, Neal 1987).
The hydoxylated (AFM1 and AFQ1 ) and 0-demethylated (AFP 1 ) metabolites of
AFB 1 can undergo glucuronidation and sulfation. Glucuronidation, catalyzed by liver
microsomal UDP-glucuronyl transferase (UDPGT), has been reported for a variety of
endogenous and foreign compounds (Burchell & Coughtrie 1989). In rat hepatocytes,
AFP 1 is a better substrate for glucuronide conjugation than AFM1 and AFQ1 (Metcalfe &
Neal 1983). AFP1-glucuronide conjugate is the only significant glucuronide or sulfate
conjugate other than the other two AFB 1 metabolites (AFM1' and AFQ 1 ) in rat liver cells
(Ch'ih et al. 1983). These conjugations results in formations of water-soluble atlatoxin
esters that are excreted in the urine or bile (Hseih & Wong 1982). Refer to Figure 2.5 for
an overview of AFB 1 metabolism pathways that lead to its toxic and carcinogenic effects.

AFB1 Metabolism in the Small Intestine and Blood, and Binding to Proteins

Although the major sites for AFB 1 metabolism are in the liver and kidney, there are
suggestions that some biotransformation may also occur in the small intestine. (Hartiala
1977; Vainio & Hietanen 1979). The intestinal mucosa contains cytochrome P450
enzymes and has been suggested to be the site for the metabolism of AFB 1 . The intestinal

15

0

0

0

0

!

50
CYP4
0

0

AFB 1-8,9-epoxide

0

0

0

Glutathione S-transferase
GSH

0

COOH
I
CRCH2.CH2.CO.NH

I

I

HO

0

AFB1-GSH
0

l
FIGURE 2. 4 AFB 1 -glutathione conjugation pathway.
Source: Neal, G.E. ( 1 987) Influences of metabolism: aflatoxin metabolism and its possible
relationship with disease. In : Natural Toxicants in Food: Progress and Prospects
(Watson, D.H. , ed.), pp. 225- 1 68. VCH Publishers, New York, NY.

16

y-glutamyltranspeptidase
y-glutamylglycylglycine

0

NH2

HO

I

CH.CH2.S

I

0

AFB 1 -Cys.Gly

�-........-<
O

0

CO.NRCH2.COOH

dipeptidase

0

0

NH2

AFB1-Cys

HO

CH.CH2.s

0

COOH

acety CoA

N-acetyltransferase

CoA

•

CH3
C=O

I

NH

AFB 1 -Nac.Cys

HO

I

CKCHi-S

I

COOR

FIGURE 2. 4 (Continued).

0

I
I

Aflatoxin

Bi

\

Phase I
CYP450,
Lipoxygenase,
PHS

AFB 1 -8, 9-epoxide

GST

Hydroxylated Metabolites

t

UDP-GT & ST (Phase II)

Glucuronide & Sulfate
Conjugates

j '

�I

Phase II

•

DNA, RNA Adducts

Repair

�

+

Mutation

t

Dihydrodiol

GSH conjugates

�

Protein Adducts

�

Cell Death

I�

FIGURE 2. 5 Overview of aflatoxin B 1 biotranformational pathways that lead to toxicity and
carcinogenicity.

Source: Eaton, D.L. & Gallagher, E.P. (1 994) Mechanisms ofaflatoxin carcinogenicity.
Ann.Rev. Pharmacol. 34: 1 35-1 72.

18
metabolism produces metabolites, such as AFB1 -epoxide, AFB2a,and AFB1 dihydrodiol,
that may bind covalently to proteins.
It has also been suggested that there is some detoxification of AFB1 metabolites in
the gut by the phase II detoxification enzymes (Hsieh & Wong 1994). This suggestion
was made due to the absence of organic-extractable AFB1 metabolites in the blood. The
authors concluded that since the liver has high capability to draw free AFB1 from the
blood, AFB1 binding to serum albumin after absorption from the intestine could be one of
the major detoxification processes of AFB 1 . At low doses of AFBi , they found no free
AFB1 in the blood. This is because the absorbed AFB 1 readily binds to albumin. Albumin
serves as the major transporter of AFB 1 in the blood since very little AFB1 was bound to
other blood proteins (Dirr & Scabort 1987). Because of the high levels of accumulation
and occurrence, serum albumin adduct is currently used as a biomarker for AFB1 exposure
in humans (Chang et al. 1994).
The presence of AFB1 -albumin adducts in serum (Sabbioni et al. 1987) indicates
that AFB1 is metabolized either in the intestine or in blood compartments. Blood platelets
contain cytochrome P450, prostaglandin synthase (Hodgston & Levi 1994) and
lipoxygenase (Liu & Massey 1992), which are capable of activating AFB1 • Therefore, it
may be that these enzymes catalyze the formation of AFB1 -epoxide found in the blood,
and that epoxide then binds to albumin. However, another study reported that a very high
percentage of AFB 1 bound to rat plasma albumin noncovalently (more than 95%)
(Ewaskiewicz et al. 1991). This indicates that AFB1 does not have to be metabolized first
for it to bind to albumin and that albumin serves as major transporter of AFB1 in the blood
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to the liver.
Hirano et al. (1994) studied the probable role ofbovine serum albumin (BSA) in
inhibiting the toxicity and absorption of AFB1 in one-day-old chicks. The BSA was given
intragastrically prior to AFB1 administration. BSA treated chicks showed less AFB1 induced liver damages such as bile duct proliferation and necrosis than did the non-BSA
treated animals. AFB1 concentrations in the liver and plasma were also lowered in the
BSA treated animals 6-h post-AFB1 treatment, at which time the AFB1 level was at the
maximum. These phenomena might be due to an increased binding of AFB1 to BSA in the
intestine. Since macromolecules (which include AFBi -BSA adduct) cannot be absorbed
from the small intestine of a one-day-old chick, it was postulated that the BSA adduct was
rapidly excreted without absorption.

AFB1 and Diet Interactions
There are many reports on the effects of various food or nutrients and xenobiotics
on AFB1 -macromolecule adducts formation. Obviously, the major objectives of these
studies have been to determine if and how those nutrients or xenobiotics could affect
adducts formation, especially DNA adduct (see Tables 2.1 and 2.2).

Fat-soluble vitamins

A number of vitamins and vitamin analogs have been tested on AFB 1 macromolecule adduct formation. Bhattacharya et al. (1984; 1987) reported
comprehensive studies on the effects of various vitamins on in vitro adducts formation.
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TABLE 2.1
Influences of dietary nutrients on AFB 1 -DNA adducts formation.

Compound*

Test System

Low Protein

Rat liver

T

Mandell et al. (1 992)

Low fat
Rat liver
(high carbohydrate)

T

Nyathi et al. ( 1 993)

Fat (Saturated or
unsaturated)

Rat liver

NSE*

Marzuki & Norred
( 1 9 8 4)

Essential oils

Rat liver microsome

l

Hashim et al. ( 1 994)

Vitamin A

Rat liver

l

Rat liver
Woodchuck hepatocyte

NSE
l

Bhattacharya et al.
( 1 9 8 9)
Chen et al. ( 1 9 8 2)
Yu et al. (1 994)

�-carotene

Woodchuck hepatocyte

T

Yu et al. (1 994)

Vitamine E

Woodchuck hepatocyte

T

Yu et al. (1 994)

Riboflavin

Rat liver

l

Webster et al. (1 996)

Vitamin B6

Rat liver microsome

NSE

Bhattacharya et al.
(1 984)

Thiamin
(1984)

Rat liver microsome

NSE

Bhattacharya et al.

Vitamin C

Woodchuck hepatocyte

l

Yu et al. (1 994)

l

Campbell et al.
( 1 9 78 )

Lipotropes (deficient) Rat liver
Continued

Increase (T)/Decrease (l)

Reference
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TABLE 2.1 : Continued

Reference

Compound*

Test System

Camitine

Rat liver

l

Choline (deficient)

Rat liver
- Single AFB 1 dose
- Multiple AFB 1 doses

NSE

T

Schrager et al. ( 1 990)
Schrager et al. ( 1 990)

Rat liver microsome

l

Bhattacharya et al.

l

Chen et al. ( 1 982)

Copper

Increase (J)/Decrease (l)

Rat liver
Selenium
(Excess or deficient)

Sachan & Yatim

(1 992)

(1 984)

Selenium

Chick liver

NSE

Chen et al. ( 1 982)

Selenium

Hamster ovary cells

NSE

Shi et al. ( 1 995)

Feed restriction

Rat liver

l

Pegram et al. (1 989)
Gao & Chou ( 1 992)
Chen et al. ( 1 995)

lndole-3-carbinol

Trout liver

!

Dashwood et al.

Trout liver microsome

l

Takahasi et al ( 1 995)

R-goitrin

Rat liver

l

Chang & Bj eldanes

Curcumin

Rat liver microsome

l

*NSE, no significant effect

(1 989)

( 1 98 7 )

Firozi et al. ( 1 996)
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TABLE 2.2
Influences of xenobiotics on AFB 1-DNA adducts formation.

Compound*

Test System

Increase (l)/Decrease (l)

Reference

Rat liver microsome

l

Bhattacharya et al. ( 1 984)

Rat liver

l

Chang & Bjeldanes (1987)

Trout liver

NSE**

Goeger et al. ( 1988)

Rat and mouse livers

l

Monroe & (Eaton 1 987)

BHT

Rat liver microsome

!

Bhattacharya et al. (1 984)

Cortisol

Rat liver

T

Chentanez et al. (1 988)

Crocetin

Fibroblast cell

l

Wang et al. ( 1 99 1 a)

DDB

Rat liver

!

Liu et al. ( 1 995)

Ethoxyquin

Rat liver

!

Kensler et al. (1 986)

Ethanol

Rat liver

!

Toskulkoa & Glinsukon
( 1 986)

Geniposide

Rat Liver
Rat liver microsome

l
l

Wang et al. ( 1 99 1b)
Wang et al. ( 1 992)

l

Lotlikar et al. 1 989)

BHA

Phenobarbital Rat liver

*BHA, butylated hydroxyanisole; BHT, butylated hydroxytoluene; DDB; dimethyl-4,4'
dimethoxy-5,6,5'6'-dimethylenedioxy biphenyl-2,2' dicarboxylate.
**NSE, no significant effect
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Vitamin A supplemention in rats inhibited AFB1 -DNA binding (Bhattacharya et al
1989). The protective effects of retinoids such as retinol, retinal, retinoic acid, and retinal
esters on AFB1 carcinogenicity were due to inhibition of AFB1 -DNA adduct formation by
affecting the CYP450 systems resulting in less epoxide being formed (Bhattacharya et al.
1984). Retinal had the same inhibitory effect on the formation of AFB1 -protein adducts
(Bhattacharya et al. 1989). Vitamin A has been shown to induce the activity of
glutathione S-transferase, thereby enhancing the detoxification of AFB1 -epoxide
(Bhattacharya et al. 1989). On the other hand, vitamin A deficiency decreased glutathione
S-transferase activity.
However, another study reported that a vitamin A supplement had no significant
effect on AFB1 -macromolecules binding in rats. On the contrary, a combined deficiency of
vitamin E and selenium decreased AFB1 binding to DNA, RNA, and protein (Chen et al.
1982). Vitamin E and menadione (a water-soluble synthetic vitamin K) have been found
to prevent AFB1 -induced mutagenesis in the Ames bacterial system (Raina & Gurto 1985).
�-carotene and vitamin E increased DNA adduct formation in woodchuck hepatocytes
(Yu et al. 1994).

Water-soluble vitamins
Riboflavin, riboflavin-5'-phosphate (FM.N), and flavin adenine dinucleotide (FAD)
inhibited AFB1 -DNA adduct formation in vitro. Riboflavin was reported as the most
effective of the three vitamins (Bhattacharya et al. 1984). It has been recently suggested
that the mechanism for the riboflavin effect is its ability to induce. the enzymes involved in
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repairing damaged DNA (Webster et al. 1996).
Vitamin C, vitamin B6 and thiamin had no significant effect on DNA adduct
production (Bhattacharya et al.1984). However, vitamin C, B6, and folic acid inhibited
mutagenesis in bacterial systems (Bhattacharya et al. 1984; Bhattacharya et al. 1987). The
inhibition by vitamin C was not as great as with the fat-soluble vitamins.
In a study employing woodchuck hepatocytes to find the role of vitamins A, C, and
E, and �-carotene on the initiation of AFB1 -induced carcinogenesis, the workers found
that vitamin A was more effective than vitamin C in inhibiting DNA adduct formation. In
contrast, vitamin E and �-carotene enhanced the binding (Yu et al. 1994). Therefore,
these results suggest that different antioxidant vitamins may effect AFB1 -DNA binding
differently.

Amino acids
There are conflicting reports on the effects of different amino acids on AFB1
carcinogenesis. A diet marginally deficient in methionine (which was also deficient in
choline and lacking in folacin) depressed DNA and RNA adducts formation in rat liver.
Protein adduct formation was not affected by the diet. The inhibition of AFB1 -nucleic acid
adducts in the marginally lipotrope-deficient diet was due to the decrease in the activation
of AFB1 and not due to an increase in glutathione levels (Campbell et al. 1978). A choline
and methionine-deficient diet fed rats showed no significant AFB1 dose-response changes
in serum biochemical parameters or liver pathology compared to the complete amino acid
diet (Mehta et al. 1993). These two studies treated the rats with a single dose of AFB 1 .
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Schrager et al. ( 1 990) found that a single dose of AFB 1 did not affect the DNA
adduct concentration in both choline-deficient and control animals. However, when
multiple doses of AFB 1 were administered, the AFB 1 -DNA adduct levels were
significantly higher in the rats fed a choline-deficient diet than in the rats fed with a control
diet. An earlier report also found that marginally deficient lipotrope diets induced AFB 1
tumorigenesis in rats (Rogers & Newbeme 1 9 69). L-carnitine supplementation in rats has
been found to decrease AFB.-DNA binding (Sachan & Yatim 1 99 2).
Sulfur-containing amino-acids such as cysteine, N-acetylcysteine, cystine,
methionine, and glutathione inhibited AFB 1 mutagenicity in microbial systems. Cysteine
and N-acetylcysteine were more potent inhibitors than glutathione. The investigators
suggested that the inhibition was due to amino acids affecting the synthesis of AFB 1 epoxide (Shetty et al. 1 989).

Protein
Weanling rats fed a low protein diet (5% casein) had fewer AFB 1 -induced
preneoplastic foci in their livers than rats fed a high protein diet ( 200/o casein) (Youngman
& Campbell 1 99 2). The enhanced development of the preneoplastic foci ( y-glutamyl
transpeptidase-positive foci) by the high protein diet was reversed when the animals were
put on a low protein diet. Thus, it was concluded that the low protein diet prevented
lesions caused by AFB 1 •
Mandell et al. ( 1 99 2) reported that AFB 1 -induced hepatocarcinogenicity can occur
in both low- and high-protein fed weanling animals. Moreover, the low protein diet ( 5%
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lactalbumin) also caused severe liver histopathological changes or sub-acute toxicity
symptoms such as necrosis and bile duct proliferation due to AFB 1 . Also,the protein
deficient animals had a more rapid decrease in glutathione S-transferase activity than the
protein-sufficient ( 2 00/o lactalbumin) animals . High protein fed animals did not show the
sub-acute toxicity responses induced by AFB 1 . Therefore,the authors suggested that
protein deficiency is more likely to enhance,rather than protect the liver against,AFB 1
toxicity and carcinogenicity.

Fat and essential oils
Di fferent types and amounts offat may have di fferent e ffects on the carcinogenesis
of AFB 1 • High polyunsaturated oil ( com oil) increased the incidence of liver cancer in rats
caused by AFB 1 as compared to rats fed with saturated oil (beef fat). The cancer
incidence was higher when the com oil was fed with or after the exposure to AFB 1 than
when the oil was fed before the AFB 1 dose. An increase in induction of AFB 1 activation
by com oil was suggested for the high cancer incidence (Newbeme et al. 1 9 7 9).
However,in a similar study,saturated ( coconut oil ) and unsaturated dietary ( com oil ) fats
were found to have no significant effect on the adduct formation and the production of
AFB 1 -epoxide in rat livers (Marzuki & Norred 1 9 8 )4.
In another report,the metabolism and mutagenicity of AFB 1 were not significantly
di fferent between mice fed with beeffat and olive oil diets (Brennan-Craddock et al.
1 9 90). With respect to the levels ofdietary fat,a low-fat (high carbohydrate) diet
increased the AFB 1 -DNA binding more than a high fat diet (Nyathi et al. 1 9 9 3) . The

27
protective effect of a high fat diet may be due to a decrease in the uptake of AFB 1 into
hepatocytes or a reduction of AFB1 -epoxide production.
Hashim et al. (1994) investigated the capability of essential oils extracted from
nutmeg, ginger, cardamom, celery, xanthoxylum, coriander, cumin, and black pepper to
inhibit AFB 1 -DNA adducts formation mediated by liver microsomal enzymes. All the
essential oils tested were suppressive to the adducts formation, and the inhibition was
dose-dependent. The modulating effect of these oils was through their ability to inhibit the
activation of AFB1 •
The presence of long chain fatty acids at their physiological concentrations
increased the strength of AFB1 -albumin binding considerably (Dirr 1987). The binding
affinity (ka) was increased by 3-fold when the pH was raised from 6 to 9. The presence of
palmitic, stearic, and oleic acids (the most abundant plasma fatty acids) at the
concentration range of0. 5 to 2.0 mol/mol albumin, further increased the albumin binding
of AFB1 to greater than 4 times at pH 7.4 (Dirr 1987).

Trace elements
Copper inhibited AFBi -DNA binding in vitro (Bhattacharya et al. 1984). A
deficiency and an excess of selenium decreased the adduct formation in rats. In chicks,
however, excess of selenium did not change the concentration of adducts formed (Chen et
al. 1982). Recently, selenium was demonstrated to have no effect on DNA adduct
formation in ovary cells and did not effect AFB1 mutagenesis (Shi et al. 1995).
Copper, manganese, zinc, and selenium were effective in preventing in vitro AFB1 -
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induced mutagenesis. Copper was the most potent among the elements tested. To a
lesser extent, iodine, molybdenum, cobalt, and iron were antimutagenic. The investigators
suggested that the inhibition was due to interaction of trace elements with the microsomal
enzymes (Francis et al. 1 988).

Feed restriction
The potentially protective effects of caloric restriction on cancer-causing
compounds has promoted considerable interest and investigation. It has been reported
that rats fed with 60% of the food consumed by ad libitum animals had lower AFB1
microsomal activation, lower AFB1 -adducts, faster plasma clearance, and increased
urinary excretion of AFB1 than the ad libitum fed animals. The authors concluded that
40% feed restriction may decrease AFB1 carcinogenicity (Pegram et al. 1 989).
Similarly, about more than 50% reduction in AFB1 -DNA binding was found when
rats were fed 40% caloric restricted diet (Gao & Chou 1 992). The restriction also
decreased the hepatic DNA double strand damage induced by AFB1 • Induction in
glutathione S-transferase activity in feed restriction will enhance AFB1 -epoxide
conjugation to GSH and thus reduce AFB1 -DNA adducts formation (Chen et al. 1 995).

Cruciferous vegetables
Cruciferous vegetables have been shown to enhance detoxification of xenobiotics
by inducing xenobiotic-metabolizing enzymes in animals and humans (Salbe & Bjeldanes
1 989). High consumption of vegetables such as broccoli, cabbage, cauliflower, and
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Brussels sprouts has been related to a reduced risk of bladder, colon, and rectum cancers
(Grahams 1983).
Brussels sprouts significantly decreased AFB 1 -DNA binding and increased the
GST activity in rats. lndole-3-carbinol, a compound found in cruciferous vegetables, did
not have much effect on the DNA binding and GST activity (Salbe & Bjeldanes 1989).
The same investigators also found that the route of administration, intragastric or
intraperitoneal, did not have a different effect on AFB i-DNA binding. Thus, they
concluded that the small intestine did not play an important role in AFB 1 metabolism.
However, in another study that utilized trout, 1000 and 2000 ppm of indole-3-carbinol
were shown to strongly depress AFB 1 -DNA adducts formation (Dashwood et al. 1989).
R-goitrin, another compound found in cruciferous vegetables, also exhibited
anticarcinogenic properties such as inhibition of AFB 1 -DNA binding, induction ofGST
activity, and enhancement ofbiliary excretion of AFB 1 in rats (Chang & Bjeldanes 1987).

Plant flavonoids and phenolic compounds
Five major derivatives of plant flavonoids, namely flavone, flavonol, isoflavone,
and flavonol, have been tested on activation of AFB 1 and AFB 1 -DNA adducts formation
(Bhattacharya & Firozi 1988). Most of the flavonoid derivatives significantly inhibited
adduct formation, and flavonols being the most potent. Flavonols also showed greater
inhibition of AFB 1 mutagenicity in bacterial system (Goeger et al. 1988).
Phenolic compounds may have protective effects against AFB 1 -induced
mutagenicity. Gallic acid, chlorogenic acid, caffeic acid, dopamine, p-hydroxybenzoic

30
acid, and salicyclic acid decreased mutation caused by AFB 1 in bacterial system containing
rat-liver microsomes. The inhibition occurred when the compounds and AFB1 were
administered concurrently (San & Chan 1987). Using the S9 liver fraction that contains
the metabolic enzymes, ellagic acid (a compound found in strawberries, grapes, and
walnuts) has been shown to be antimutagenic against AFB1 in bacterial assay (Loarca-Pina
et al. 1996). The inhibition was greatest when the acid was incubated together with AFB1 .
Curcumin, a phenolic compound extracted from tumeric, was recently reported to
inhibit the production of AFB1 -epoxide by affecting CYP enzyme function (Firozi et al.
1996). The inhibition became higher as the curcumin concentration was increased in the
incubation mixture. However, the suppression was reversed when the CYP level in the
mixture was higher.

AFB1 and Drugs!Xenobiotics Interactions

Antioxidants
Rats fed a butylated hydroxyanisole (BHA)-containing diet had lower AFB1 -DNA
binding, higher GST activity, and higher biliary excretion of AFB1 (Chang & Bjeldanes
1987). Animals treated with butylated hydroxytoluene (BHT) before or together with
AFB 1 had lower cancer incidences than the animals administered AFB1 alone (Dragon and
Pitot 1994). However, in trout, BHA did not effect liver tumor incidence, AFB1 -DNA
binding, or AFB 1 -glutathione conjugation (Goeger et al. 1988). In in vitro system, both
BHA and BHT inhibited AFB1 -DNA binding (Bhattacharya et al. 1984). Another
antioxidant, ethoxyquin, also suppressed AFB1 carcinogenesis by inducing the activity of
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glutathione S-transferase activity (Kensler et al. 1 986).

Ethanol
Ethanol is a known carcinogen or procarcinogen (Yirmaya & Taylor 1 993).
Ethanol is metabolized in the liver by alcohol dehydrogenase, microsomal ethanol
metabolizing system (MEOS), and catalase (Odeleye & Watson, 1 992). CYP2E l enzyme
( also known as rat P450j) is the major :MEOS that is influenced by ethanol. The induction
of CYP2E 1 by ethanol consumption was implicated in alcohol-induced liver diseases
(Nanji et al. 1 994). CYP2El has also been reported to activate certain liver toxins and
chemicals (lngelman-Sunberg et al. 1 988).
Ethanol, when given to animals together with or prior to aflatoxin, increased the
aflatoxin hepatotoxicity and DNA binding (Toskulkoa & Glinsukon 1 986; Toskulkoa et al.
1 99 1 ; Sahaphong et al. 1 992). The alcohol pretreatment increased the activation of AFB 1
but not the GST activity. This explains the increased binding of AFB 1 to DNA. On the
other hand, when given after AFB 1 administration, ethanol showed no influence on AFB i 
DNA binding (Messlbeck et al. 1 984).

Other Drugs/Xenobiotics
The activities of CYP, GST, and UDPGT enzymes can be induced by several
drugs or xenobiotics. Enzyme inducing drugs such as phenobarbital ( anti-seizure drug)
and Aroclor 1 254, given before or together with AFB i , reduced the number of neoplasms
as compared to animals given AFB 1 only (Dragan and Pitot 1 994). Although phenobarbital
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enhanced AFB 1 activation, it also induced GST activity and thus increased AFB1 glutathione conjugation. Therefore, the overall hepatic binding of AFB 1 to DNA is
reduced (Loury et al. 1 984; Lotlikar et al. 1989). Other inducers such as ethoxyquin
(Kensler et al. 1986), and oltipraz (Primiano et al. 1995), have also been shown to inhibit
AFB 1 -induced carcinogenesis by inducing GST activity. In a study employing human
hepatocytes, oltipraz was also reported to lower the the production of AFB 1 -epoxide by
inhibiting the CYP1A2 and CYP3A4 activities (Longouet et al. 1995).
A compound isolated from a Chinese herb, dimethyl-4,4'dirnethoxy-5,6,5',6'
dirnethylenedioxy biphenyl-2,2'-dicarboxylate (DOB), is a drug used for its liver protective
effects. Pretreatment of rats with DOB inhibited liver damage caused by AFB 1 • DOB also
induced the activity of glutathione S-transferase and therefore enhanced detoxification of
AFB1 -epoxide (Liu et al. 1995). Crocetin, a carotenoid isolated from the seeds of Cape
jasmine, has been reported to elevate the cytosolic glutathione S-transferase activity and
glutathione concentration in a fibroblast cell line treated with AFB1 (Wang et al. 1991a).
Another Chinese herbal drug, geniposide, isolated from a fruit of a species of gardenia,
can also inhibit AFB 1-induced DNA binding. Induction of glutathione S-transferase and
gamma glutamyl cysteine synthase (involved in glutathione synthesis) activities, and
suppression of AFB1 -induced unscheduled DNA synthesis were the suggested mechanisms
of action of geniposide (Wang et al. 1991b; Wang et al. 1992).
Cortisol pretreatment in rats markedly increases the acute hepatoxicity of AFB 1
(Chentanez et al. 1988). The toxicity effects, such as higher mortality rates, increased in
liver triacylglycerol, and elevated AFB 1 binding to DNA and protein, were dose-
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dependent. These cortisol effects may by due to increased metabolism of AFB1 to its
epoxide derivative.

Carnitine

History
Carnitine was discovered from muscle extracts by two Russian scientists in 1905
(reviewed by Leibovitz 1984). It was named carnis, which is a Latin word for flesh or
meat. In the l 940's, camitine was found to be essential for the mealworm by Fraenkel and
was named Vitamin Bt. In the late l 9SO's and early 60's, it was discovered that camitine is
involved in the transportation of fatty acids into the mitochondria for P-oxidation (Fritz
1959). However, it was not until 1973 that camitine gained much attention and
investigation, when the first camitine deficient patient was described (Engel & Angelini
1973).

Chemistry and Dietary Sources

Carnitine is a quarternary amine and is very similar to choline and amino acids.
However, unlike amino acids, carnitine does not involve in protein synthesis. Chemically,
it is known as 3-hydroxy-4-N-trimethylamino butyric acid. It exists as D and L isomers,
but only the L-isomer is biologically active. The D-isomer is not only inactive, it can also
depress L-carnitine utilization (reviewed by Leibovitz 1987). Carnitine is present in the
body as free camitine and as acylcamitine (fatty acyl-camitine ester).
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Camitine can be produced in the body, and therefore it is not essential to humans
and is not considered to be a vitamin. Muscle, liver, yeast, and milk are very good sources
of dietary camitine. Most vegetables and grains such as cauliflower, cabbage, spinach,
barley, and rice have very little or no camitine. The detailed reviews of carnitine history,
biosynthesis, dietary sources and functions are available (Leibovitz 1 984; Leibovitz 1987;
Borum 1983).

Structure of L-Carnitine

Carnitine Biosynthesis
The biosynthesis of carnitine starts from two essential amino acids, lysine and
methionine, and involves five different enzymes in a five step pathway (Figure 2.6).
Niacin, vitamin B6, vitamin C. and iron are also required for for the biosynthesis of
carnitine in animals (Borum 1 983).
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FIGURE 2. 6 Biosynthesis of carnitine.
Source: Leibovitz (1 984) Carnitine: How it functions in your body. In:
Carnitine: The Vitamin Bt Phenome� pp 24-38. Dell Publishing Co., Inc.,
New York.
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In rats, the first 4 steps of the pathway occur in the liver, kidney, skeletal muscle,
cardiac muscle, testis, and epididymis. However, the final step occurs only in the liver. In
humans, the liver, kidney, brain, heart, and skeletal muscle can convert N-trimethyllysine
to 4-N-trimethyllyamino butyric acid (Rebouche & Engel 1 980). However-, only the liver,
kidney, and brain can convert 4-N-trimethyllyamino butyric acid to carnitine. This is
because the enzyme that catalyzes the final step, butyrobetaine hydroxylase, is only present
in these three tissues. Therefore, carnitine must be transported to those tisues that do not
have the final enzyme.

Camitine Functions

The main function of carnitine is the transport of long-chain fatty acids from the
cytosol into the mitochondria for P-oxidation to take place. In brief, other possible roles
of carnitine include the regulation of cellular concentration of free CoA, metabolism of
branched chain amino acids, removal of short-chain and medium-chain acyl residues
accumulated in the peroxisomes, initiation of ketogenesis, interaction with membranes to
alter their physiological functions, prevention of fatty liver development due to
xenobiotics, and detoxification of some drugs (for reviews on carnitine roles refer to
Borum 1983; Carter et al. 1995; Frenkel & McGarry 1 980; Leibovitz 1984; Leibovitz
1 987; and Famularo, G. & De Simone, C. 1 995).
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Carnitine and Drug/Xenobiotic Interactions
Alcohol
It is widely known that chronic alcohol consumption inhibited � -oxidation and
thus causes fatty infiltration in human and experimental animal livers (Leiber et al 1987).
Impaired oxidation and/or increased lipogenesis are suggested mechanisms for the malady.
In additio� ethanol depresses camitine palmitoyltransferase 1 activity, the rate-limiting
enzyme in the translocation of long-chain fatty acids across the mitochondrial membrane
(Guzman & Geelen 1988). This inhibition may also contribute to the fat accumulation in
the liver due to alcohol consumption. Supplementary L-carnitine has been found to inhibit
alcohol-induced fatty liver (Sachan et al. 1984; Sachan & Rhew 1983). Retardation of
ethanol oxidation found in rats may be one of the mechanisms for the ameliorating effect
of camitine (Mynatt & Sachan 1992). Carnitine also delayed ethanol oxidation and
therefore augmented the half-life of ethanol in broilers (Smith et al. 1994). L
acetylcamitine and L-camitine reduced the rate of ethanol oxidation in rat hepatocytes
(Cha & Sachan 1995). The underlying mechanism for these effects of carnitine is that
camitine competitively inhibits alcohol dehydrogenase when the NAD:acetylcarnitine ratio
is less than 1 (Sachan and Cha 1994).
Carnitine appears to offer protection against the toxicity of industrial alcohols such
as methanol, isopropanol, and ethylene glycol (a common antifreeze). This is because
carnitine has been shown to prevent accumulation of these alcohols by enhancing their
excretion in the urine (Brothers 1989). Carbon tetrachloride administration causes fat
accumulation in rat liver, which is ameliorated by carnitine supplementation (Sachan &
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Dodson 1 992).

Carnitine may also alleviate the side-effects of adriamycin (doxorubicin
hydrochloride), a widely used anti-cancer drug. It has been reported that carnitine
treatment decreased histopathological changes and ameliorated irregular heart
performance due to adriamycin (Senekowitsch et al. 1987). Furthermore, camitine
prolonged the survival rate of mice administered with adriamycin (Strohm et al. 1 982).
Valproic acid, an anticonvulsant drug, has produced very serious side-effects
similar to Reye's syndrome (stupor, hyperammonia, coma, and hepatic dysfunction)
(Gerber et al. 1979). Valproic acid treatment in epileptics lowers the serum free carnitine
and increases the short-chain acylcamitine concentrations (Rodriguez-Segade et al.
1 989). Carnitine has been found to conjugate with valproic acid and other drugs, such as
cyclopropanecarboxylic acid and pivalic acid. These conjugates are excreted in the urine
(Quistad et al. 1986; Vickers et al. 1985). However, in another study with rat
hepatocytes, glycine, but not L-carnitine, prevented lactic acid dehydrogenase leakages (an
indicator of cytotoxic effect) induced by valproate (Vance et al. 1994)
Carnitine also decreased the toxicity of ifosfamide therapy. Ifosfamide, a drug
used for cancer chemotheraphy, has been known to cause symptoms such as severe
decreased in the concentrations oftricarboxylic acid cycle intermediates (succinate,
fumarate, citrate, and a:-ketoglutarate) in the urine. When rats were supplemented with L
camitine and later injected with this drug, the rats showed better health and had a lower

39
decrease in intermediary products in the urine. The authors suggested that camitine may
form a complex with ifosfamide, known as chloroacetylcamitine, that reduces the toxicity
of the drug (Schlenzig et al 1995).

AFB1 and Lipopolysaccharide �PS)
The effects ofL-camitine on AFB 1 binding to hepatic DNA, RNA, and protein are
shown in Table 2.3. L-carnitine supplemented diet fed to rats decreased the binding of
AFB 1 to liver DNA and RNA 6-h post AFB 1 administration (Sachan & Yatim 1992). The
total amounts of AFB 1 present in the liver and kidney were not significantly different
between the carnitine supplemented and control animals (Table 2.4). However, the
concentrations of AFB 1 were higher in the plasma of carnitine supplemented rats than the
non-supplemented rats. We had also shown that carnitine ameliorated the earlier signs of
acute toxicity of AFBi, such as the elevation of total lipid concentration in the liver and
the decrease in total lipids and triacylglycerol concentrations in the plasma (Sachan &
Yatim 1992).
LPS or endotoxin is a constituent of the cell wall of Gram-negative bacteria.
Injection or infiltration of LPS into the body triggers the prodution of cytokines that may
result in increased lipogenesis, hypertriglyceridemia, and in severe cases, septic shock.
Carnitine-treated animals exposed to endotoxin have been shown to have higher survival
rates (Takeyama et al. 1989), lower plasma triacylglycerol, inflammatory cytokines levels,
and fat synthesis in their livers (Gallo et al. 1993; Winter et al. 1995).
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TABLE 2.3
Effects of L-camitine supplement on atlatoxin B1-macromolecules adducts
formation in rat liver 6-h post-atlatoxin B 1 administration 1
Group
Parameter

Control

L-Camitine2

Different (%)

pmollmg macromo/ecu/es3

AFB i-Protein
1

6. 8 ± 2.8a

4.7 ± 2. 9b

30.9

2 1 . 6 ± 0. 3 a

1 4. 3 ± 0. 5b

3 3.8

1.2 ± o.r

1 . 2 ± O.l a

0

Values are mean ± SEM, n = 5.

2Diet contained 0.4% L-carnitine (w/w) and given to animals for 6 weeks.
3

Different letters indicate significant difference between groups (p < 0.0 5).
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TABLE 2.4
Tissues and plasma (3H] atlatoxin B1 concentrations in rats supplemented with L
camitine 6-h post-aflatoxin B1 administration 1

Group

Control

L-Camitine2

Different (%)

Liver, nmol AFB1 lg3

3 . 81 ± 0. 28a

3. 2 5 ± 0. 28a

1 4. 7

Kidney, nmol AFB1 lg

0. 68 ± 0.08a

0. 6 6 ± 0.07a

2. 5

Plasma, nmol AFB1 /di

2 47 ± 1 4a

3 10 ± 41 b

2 5. 8

Values are mean ± SEM, n = 5.

1

2

Diet contained 0. 4% L-carnitine (w/w) and given to animals for 6 weeks.

Different letters indicate significant difference at p < O. 05

3
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Apoptosis
The effect of carnitine on "programmed" cell death (apoptosis) has been studied.
When carnitine and its analogs were incubated in C2. 8 hepatocytic cell line incubation
mixture, the survival and growth rates of the cell were enhanced (Revoltella et al. 1 994).
Camitine also delays the onset of apoptosis induced by the deprivation of hepatocyte
growth factor, a factor necessary for the cell growth and survival. In another study
involving P 19 teratoma cells, acetylcarnitine prolonged cell survival time and delayed
DNA fragmentation and nuclear condensation caused by serum deprivation (Galli &
Fratelli 1993). These findings suggest that carnitine may serve as a cytoprotective
biomolecule; that is, it buffers the impact of certain harmful agents or conditions.

Cytochrome P450 (CYP)

CYP is a group of iron-containing enzymes important in the metabolism
(oxidation) of various endogenous (fatty acids, bile acids, steroids, biogenic amines,
prostaglandins, and leukotrienes) and foreign compounds (drugs, environmental
pollutants, alcohol, and natural plant products). Its name derives from the maximum
absorption wavelength (450 nm) produced when CYP is reacted with carbon monoxide.
It is found in the microsomes or the endoplasmic reticulum (ER) of the cell. CYP is
isolated by homogeniz.ation of the liver and followed by ultracentrifugation of the
postmitochondrial supernatant fraction. There are two types of ER, rough and smooth,
which are differentiated by the presence or absence of ribosomes, respectively. The
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smooth ER has higher oxidative activity of CYP than does rough ER. The organs where
CYP is found include skin, liver, kidney, testes, ovaries, bladder, aorta, placenta, lung,
nasal mucosa, blood platelets, gastrointestinal cells, and lymphocytes (Hodgston & Levi
1994).

There are about 67 different isoenzymes ofCYP families 1, 2, and 3 (CYP l,
CYP2, and CYP3) that participate in the biotransformation of toxic materials (Netter
1994). The metabolism of xenobiotics by CYP enzymes can either activate the

compounds to become carcinogens or detoxify the compounds. The reactions that CYP
catalyzes include epoxidation, hydroxylation, dealkylation or 0-demethylation, oxidative
deamination, oxidation, and desulfuration.

Glutathione S-Transferase and Glutathione

Glutathione S-transferases (GST) are a group of enzymes found in liver, kidney,
lung, spleen, small intestine, brain, heart, ovary and testes (Kraus & Kloft 1980). One of
GST's primary functions is the metabolism of drugs and xenobiotics, that is, catalyzing the
conjugation of reduced glutathione (GSH) to the electrophilic center of the foreign
compounds. This conjugation is the initial step in the synthesis of mercapturic acid. GST
has many isozymes, and in mammalian species the isozymes are being classified as alpha
(intermediate molecular weight), mu (highest molecular weight), and pi (lowest molecular
weight) (Dauterman 1994).
Glutathione is the most abundant (> 900/o) intracellular non-protein thiol in animal
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organs. It is a tripeptide made-up of glutamate, glycine, and cysteine. In mammalian
livers, GSH represents more than 95% of total glutathione concentration (4 to 8 mM), the
rest being oxidized glutathione (GSSH). GSH plays an important role in regulation of
enzyme activities by disulfide (thiol) exchange and binding of proteins. In liver cells, most
of GSH is found in the cytosol and about 10- 1 5% is found in the mitochondria.
Besides conjugating to reactive xenobiotics, glutathione is also involved in other
cellular defense mechanisms such as detoxification of lipid peroxides and free radicals,
regulation of protein synthesis, and maintenance of immune function (Vina 1 990).
Depletion of GSH can be directly due to conjugation to electrophiles or inhibition of GSH
synthesis. Decreased level of GSH has been correlated to the pathogenesis of liver
disease, AIDS, and cataracts. Low cellular concentration of GSH is dangerous since that
increases the susceptibility of the cell to injury due to toxic challenge (see Figure 2. 7 for
GSH homeostasis). Carbon tetrachloride, bromobenzene, and acetaminophen are a few
examples of compounds that can deplete tissue levels of GSH (Reed 1 994).
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P.E., eds.), pp. 265-296. Appleton & Lance, Norwalk, CT.
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CHAPTER 3

Effects of L-Camitine Dosage on Aflatoxin B 1-Macromolecule Adducts Formation,
Glutathione S-Transferase Activity, Glutathione Contents, and Aflatoxin B 1 Uptake
in Freshly Isolated Hepatocytes

Introduction

Aflatoxin B 1(AFB 1 ) is a well known potent hepatotoxic (O'Brien et al. 1983) and
hepatocarcinogenic (Adamson et al. 1976) mycotoxin. It has been frequently found to
contaminate many foods such as com, barley, rice, peanuts, and peanut butter. Once
AFB 1 is consumed, it is easily absorbed in the small intestine and goes into the liver via the
portal vein. In the liver it then undergoes several biotransformational pathways that
produce the reactive AFB 1 -8,9-epoxide or the less toxic hydroxylated metabolites
(reviewed by Eaton et al. 199 4).
AFB i -epoxide is the ultimate carcinogen that covalently binds to cellular
macromolecules, namely protein, DNA, and RNA. The covalent bindings are the means
by which AFB 1 exerts its toxic and carcinogenic effects. AFB i-epoxide may also undergo
detoxification by conjugating to reduced glutathione ( GSH), a process catalysed by
glutahione S-transferase (GST). This conjugation is the principal detoxification pathway
of AFB 1 -epoxide in many mammals. The cytosolic GST activity has been correlated to
susceptibility of several animal species to AFB 1 carcinogenicity ( Eaton & Gallagher
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1994).
L-camitine, 3-hydroxy-4-N-trimethylamino butyric acid, is an important
biomolecule for the intramitochondrial translocation of long chain fatty acids and many
other emerging roles in health and disease (Ferrari et al. 1992). We reported earlier that a
0.4% carnitine supplemented diet fed to rats decreased the binding of AFB1 to hepatic
DNA and RNA 6 h and 24 h post-AFB1 administration (Sachan & Yatim 1992). The
AFB1 dose (1 mg/kg) was given orally, 6 week after the animals were started on the diet.
Camitine significantly reduced AFB 1 -protein adduct formation 24 h after the AFB1 dose.
Carnitine supplementation also prevented hepatic steatosis and hypolipidemia caused by
AFB1 .
Therefore, the primary objective of this study was to understand the mechanisms
by which carnitine modulated the AFB1 -DNA adducts formation. Since it was decided to
use freshly isolated rat hepatocytes, we first investigated the effect of carnitine on AFB1 macromolecules adducts formation in these hepatocytes. The possible role of carnitine in
inducing the activity of GST and increasing total glutathione concentration were studied
since GST and glutathione are involved in the detoxification of activated AFB1 . The
uptake of AFB1 by hepatocytes in the presence of carnitine was also investigated because
if carnitine could reduce the cellular uptake of AF'Bi, that would reduce the exposure of
macromolecules to AFB1 .
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Materials and Methods

Animals
The research protocol was approved by the Animal Care and Use Committee of
the University of Tennessee, Knoxville. Male Sprague Dawley rats weighing 300-350 g
were housed individually in suspended stainless steel cages in a cubicle of an AAALAC
approved animal facility. The animals were given free access to Teklad 22/5 Rodent Diet
(W) 8640 (Harlan, Indianapolis, IN) and chlorinated water.

Liver Perfusion and Isolation ofHepatocytes
Buffers
The buffers used for preperfusion, collagenase perfusion and incubation were
modified Hank's balanced salt solutions as described by Lotlikar et al. (1 989). All buffers
were saturated with 95% 02 + 5 % CO2 gas before use. (Refer to Appendix 1 for
detailed procedures for liver perfusion and isolation of hepatocytes). The pre-perfusion
modified Hank's buffer contained 0.5 mM EGTA, 25 mM HEPES, and 0.5% BSA (added
prior to perfusion) but had no ca++ or Mg++. The perfusion buffer was a modified Hank's
buffer having 2 mM CaC12, 0.5 mM EGTA, 25 mM HEPES, 0.5% BSA, and 0.05%
collagenase (type IV). The solution was saturated with 95% 02 + 5% CO2 gas before
the addition of BSA and collagenase just prior to perfusion. The incubation buffer was
similar to the collagenase buffer except it had no collagenase.
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Liver perfusion
The perfusion apparatus and procedures used were according to the modified
methods of Seglen (1976). Rats were anesthetized with metofane (Pitman-Moore, Inc.
Mundelein, IL) by the open-drop method in a closed jar. The portal vein was cannulated
and ca++- and Mg++-free (preperfusion) buffer was injected at a flow rate of30 ml/min for
about I min while the cannula was secured with ligature. The buffer flow was then
increased to 50 ml/min, and the anterior vena cava was cut to let the perfusate escape.
After starting the perfusion (2-3 min), the intact liver was carefully removed from the rat
and placed flat on the perfusion dish for continous perfusion with 500 ml of the
preperfusion buffer for about I O min. Then, the collagenase buffer was introduced at the
flow rate of 50 ml/min for about 10 min. One hundred ml of 0.05% collagenase buffer
was used and recycled during the course of the perfusion. The liver swelled to about
twice its original size at the end of the collagenase perfusion. The liver was placed on a
watch glass containing 5 ml of the incubation buffer (containing 0.5% BSA), and was
carefully raked with a stainless steel fork to release the cells from the connective tissue and
vascular stroma.

Hepatocyte isolation and viability test
The liberated cells were suspended in I O ml of ice-cold incubation buffer
containing 0.5% BSA and were centrifuged at 50 x g for 3 min at 4 °C. The loose cells
and supernatant were removed. After this time, the cells were placed in an ice-bucket
(temperature at about 4 °C). The heavy cell pellet was resuspended with 20 ml of
incubation buffer containing 0.5% BSA and centrifuged as above. The supernatant and
loose cells were discarded. These steps were repeated two more times to ensure maximal
removal of dead cells and other cells (macrophage and fat cells). The hepatocyte pellet
was suspended and made up to a 20 ml suspension with the incubation buffer containing
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0.5% BSA. For viability test, the hepatocyte suspension was diluted 1 : 10, and 100 µI of
the diluted cells were added to 100 µI of0.6% trypan blue and counted using a
hemacytometer (see details in APPENDIX 1).
Hepatocytes incubation
The hepatocytes incubation was done according to the method by Lotlikar et al.
(1 987). In brief, the incubation mixtures contained 4 x 1 06 cells/ml, modified Hank's
buffer (pH 7.4) containing 2 mM CaC12, 25 mM HEPES, 0.5% bovine serum albumin
(fatty acid-free), various levels of L-carnitine (0 - 1 .5 mM), and 0.5 µM [3H]AFB1 (0.5
µCi/ml). [3H]AFB1 was dissolved in dimethylsulfoxide (DMSO), and the final
concentration of DMSO was 2%. The incubation medium was saturated with 95% 02 +
5% CO2 gas before addition to the mixtures. The incubation volume was 5 ml, and
incubation was conducted in duplicates or triplicates in Erlenmeyer flasks. Carnitine was
preincubated for 1 5 min before adding the [3H]AFB 1 and incubated further for 60 min. At
the end of incubation time, the flasks were immediately dipped into an ice-water bath
before further manipulations were carrired out.
Extraction and Isolation ofMacromolecules
The extraction and isolation of DNA, RNA, and protein were carried out
according to Glazer's & Weber's (197 1) method (Appendix 2). Briefly, the homogenized
hepatocytes were treateded with perchloic acid (PCA) to precipitate the macromolecules,
and were centrifuged at 2700 x g for 1 5 min at 2 °c. The pellet was treated with
potassium acetate, chloroform: ethanol, and absolute ethanol to remove lipids. The pellet
was resuspended with PCA, left overnight, and centrifuged. The supernatant contained
RNA. The pellet was resuspended in PCA and heated at 70 °C for 20 min. After
centrifuging, the supernatant (DNA fraction) was collected. The pellet was washed with
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double deionized water (DOW) and was centrifuged. The pellet containing the protein
fraction was suspended by adding potassium hydroxide and heating at 70 °C for 15 min.
In experiments where only DNA was extracted, the procedures of Gross-Bellard et
al. (1973) were followed (Appendix 3). In short, at the end of the incubation period, the
hepatocytes were centrifuged at 500 x g for 5 min to sediment cells. The supernatant was
discarded. The cells pellet was suspended with 0.3 ml digestion buffer (containing
I OOmM NaCl, I O mM Tris-CI, pH 8.0, 25 mM EDTA, pH 8.0, 0.5% SDS, and 0. 1 mg/ml
proteinase K) and incubated at 50 °C in a shaking water-bath for 12-18h. Then, 0.3 ml
digestion buffer (without proteinase K) was added and mixed. DNA was extracted with
0.6 ml of phenol:chloroform:isoamyl alchohol (25:24: 1), and was centrifuged at 1700 x g
for 10 min. To the aqueous layer 250 µI of3.0 M sodium acetate and 1 ml of 100%,
alcohol were added. After centrifuging at 1700 x g for 2 min, the supernatant was
discarded, and the pellet was washed with 70% EtOH. The pellet (crude DNA) was dried
in a "Speedvac Concentrator" for I min, suspended in 1 ml of 10 mM Tris-CI (pH 7.4)
containing lmM EDTA, and was shaken to aid solubilization at room temperature or at 65

c for several hours.

0

RNA was removed by adding 0. 1 % SDS and 1 µg/ml DNAase-free RNase and
incubated at 37 °C for 1 h. DNA was again extracted as described above and solubilized
in I

ml

of IO mM Tris-Cl (pH 7.4) containing lmM EDTA.
The content of DNA was determined colorimetrically using calf thymus DNA as

standard (Ceriotti 1952) (APPENDIX4). The RNA was measured
spectrophotometrically using yeast RNA as standard at 260 nm (Glazer & Weber 197 1).
Protein was measured by the method of Lowry et al. (195 1) (APPENDIX 5).
fHJAFB1 radioactivity measurement
Radioactivity or disintergration per minute (DPM) was measured by transfering
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0.5 ml of DNA, RNA, and protein extracts into scintillation vials, added with 5 ml
Aquasol-2 (Dupont-NEN Research Products, Boston, MA) and counted in a liquid
scintillation counter (LS-3801 Beckman Instrument, Irving, CA) for 10 min. For protein,
0 .1 ml of glacial acetic acid was added to decrease random coincidence monitor (RCM)
before counting.
Determination of GST activity
Cytosolic GST activity was determined according to the method by Habig et al.
(1974) (see Appendix 6 for complete procedures). In brief: the incubation mixture was
homogenized in 3 complete strokes in a Potter-Elvehjem homogenizer. The cell
homogenate was centrifuged at 9,000 x g for 15 min in a swinging bucket. The
supernatant was centrifuged at 100,000 x g for 60 min and the resulting supernatant
(cytosol) was assayed for GST activity. The changes in absorbance of the reaction
mixture containing the cytosol minus blank were monitored at 340 nm at 25 °C for 3 min
in an Hitachi U-2000 double-beam spectrophotometer. The results were reported as µmol
S-(2,4-dinitro-1-benzyl)glutathione formed /mg cytosolic protein/min. The cytosolic
protein content was assayed according to Lowry's method (1951), using BSA as standard.

Determination of total glutathione concentration
Total glutathione was assayed according to the method of Griffith (1985) as
described by Anderson (1985) (Appendix 7). After incubation, 100 µI of incubation
mixture was transferred into microcentrifuge tubes containing 100 µI of 1O mM HCI. The ·
cells were lysed by freezing in liquid nitrogen and thawing four times. After centrifuging
at 10,000 x g for 5 min, 100 µI of the supernatant was added with 50 µl 10% sulfosalicylic
acid to precipitate protein. The protein-free supernatant (25 µI) was mixed with 0.2 mM
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NADPH, and 0.6 mM 5,5'-dithiobis-{2-nitrobenzoic acid (DTNB), and preincubated at 37
�C for 3 min. Then 1.3 - 2.6 U glutathione reductase was added to start the reaction. The
rate of change of absorbance was monitored for 3 min. The concentration of total
glutathione was calculated from a standard curve using known concentrations of GSH.
Determination of uptake ofAFB1 by hepatocyes
After incubation with carnitine and [3H]AFBi , the hepatocytes were separated
from the incubation medium by centrifugation at 500 x g. After washing the cells with
incubation buffer (no BSA), the cells were again centrifuged, resuspended, homogenized,
and centrifuged at 600 x g for I O min to pellet the nuclei. The post-nuclear supernatant
was separated from the nuclear pellet. The nuclear pellet was suspended in incubation
buffer. The incubation medium, washed cells suspension, nuclear pellet suspension, and
post-nuclear supernatant were extracted with chloroform:ethylacetate (I : I ) to remove free
AFB 1 • Aliquots of these extracted fractions were measured for radioactivity (DPM) in a
liquid scintillation counter for I O min.
Statistics
All data were expressed as group mean ± SEM. The data were analyzed using
regression procedure of SAS (SAS Institute, Inc., Cary, NC). The regression curve was
plotted using Excel 5.0 software for Windows. The minimum level of significance was set
atp s 0.05.

Results
AFBrMacromolecules Adducts Formation
Regression analyses were used to examine the correlations of L-carnitine

54
concentrations on AFB 1 binding to DNA, RNA and protein ofisolated hepatocytes. As
shown in Figure 3.1, as the concentrations ofcamitine increased from 0-400 µM, the
concentrations ofAFB 1 -DNA adducts were linearly decreased in the cells (r = -0.52; p =
0.039). In the next experiment, a higher range ofcamitine concentrations (0-1 500 µM)
was preincubated with the hepatocytes to raise the intracellular camitine concentrations
that would affect the DNA adducts formation. When higher levels ofcamitine were
tested, the correlation ofcarnitine and DNA adducts was stronger (r = -0.68 1 ), and the
significance level was better (p = 0.0002) (Figure 3.2). The carnitine effect on the DNA
adducts formation seems to have flattened at the carnitine concentrations from 1 200 µM
to 1500 µM. As a result, 1200 µM concentration was used in experiments where a single
concentration ofcarnitine was required, such as experiments described in Chapter 4.
Carnitine did not affect the AFB 1 -RNA adducts formation (Figure 3.3) in the
hepatocytes. The concentrations ofAFB 1 -RNA adducts remained unchanged as the
concentrations ofcarnitine were increased. However, as for AFB 1-protein adducts,
regression analysis shows that carnitine had a significant positive correlation (r = 0.5845; p

= 0.0 1 7) on the protein adducts production (Figure 3.4). These RNA and protein
adducts results are different from what were found in the in vivo study (Sachan & Yatim
1 992). In rats, carnitine supplementation significantly decreased the binding ofAFB 1 to
liver RNA (and DNA), but did not affect on binding to liver protein at 6-h post AFB 1
adrninisteration.

Effect of carnitine on glutathione S-transferase activity (GST) and total glutathione
(GSH + GSSH)
GST is an important detoxification enzyme that catalyses the conjugation ofAFB 1 epoxide to GSH. Figure 3.5 illustrates the effects ofcamitine on GST activity toward 1 -
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chloro-2,4 dinitrobenzene in hepatocytes exposed to AFB 1 . The activity of GST was not
affected by camitine. However, the total glutathione concentrations were positively
correlated (r = 0. 4 1 ; p = 0. 041) to camitine levels added to the hepatocytes (Figure 3.6).
This indicates that camitine has a protective effect on the decrease in the cellular total
glutathione contents caused by AFB 1 .
Effect ofcamitine on uptake ofAFB1 by hepatocytes and cellular compartments
The entry of AFB 1 into hepatocytes and consequently into the nuclei is an
important determinant for the amounts of AFB 1 available for bioactivation and binding to
macromolecules. Therefore, inhibition of AFB 1 entry into the cells may account for the
lower concentrations of AFB 1 -DNA adducts in camitine treated animals and hepatocytes.
However, as shown in Figure 3.7, camitine had no significant effect on the entry of AFB 1
into hepatocytes, nuclei, or post-nuclear supernatant.

Discussion
AFB1-macromolecule adductsformation
Our previous studies with intact rats showed that carnitine supplementation
decreased hepatic covalent binding of AFB 1 to DNA, RNA, and protein 24-h post AFB 1
treatment. (Sachan & Yatim 1992). The present investigation with freshly isolated
hepatocytes also showed that an increasing dosage of camitine linearly decreased AFB i 
DNA adduct formation. When higher range of camitine concentrations (0 to 1 .5 mM)
were present in the hepatocytes' incubation system, the correlation was stronger than when
lower range (0 to 0.4 mM) of carnitine concentrations was used. In contrast to the in vivo
study, camitine linearly increased the AFB1 -protein adducts concentration, and had no
significant effect on AFB 1 -RNA adduct concentration in isolated hepatocyes.
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The covalent binding of AFB 1 to DNA is an important step in AFB 1 carcinogenesis
(Eaton & Gallager 1994), and AFB 1 -protein adduct is currently used to assess human
exposure to AFB 1 (Sheabar et al. 1993; Chang et al. 1 994). Therefore, several follow-up
experiments were conducted to study the biochemical basis for the carnitine's effects on
the formation of these two adducts (see CHAPTER 4).
The protective mechanisms suggested for crocetin (a carotenoid) on the AFB1 DNA adduct fonnation (Wang et al. 1991a) may also apply for carnitine, that is, carnitine
may suppress the bioactivation of AFB i , induce the detoxification of activated AFB 1 , and
act as an antioxidant that scavenges AFB1 free radicals or peroxides that are produced
when AFB 1 is metabolized by prostaglandin H synthase and lipoxygenase. Prostaglandin
H synthase (Lui et al. 1990) and lipoxygenase (Lui & Massey 1992) are the other
metabolic pathways not involving the cytochrome P450 system that can bioactivate AFB 1 .
Carnitine increased glutathione concentration in the cells treated with AFB 1 , which is
similar to the effect of crocetin (and will be discussed later in this Chapter). Carnitine has
been shown to inhibit formation of oxygen-free radicals and increase the repair rate of
DNA in human cells (Marini et al. 1990; Monti et al, 1992).
The elevation of AFB1 binding to protein in the hepatocytes system is an important
observation. In intact animals, carnitine had no effect on AFB1 -protein interaction when
measured at 6-h after AFB1 administration. However, at 24-h post AFB 1 treatment,
carnitine decreased the AFB1 -protein concentration (Sachan & Yatim 1992). One reason
for this difference may be that in the hepatocytes' incubation medium, 0.5% BSA was
added to keep the cells intact longer when incubating with noxious agents (Berry et al.
1991). We have found that carnitine enhances the binding of AFB 1 to BSA (in the
presence or absence of microsomes) and to rat plasma protein (CHAPTER 4). The
higher amount of microsomal-activated AFB 1 binding to BSA mediated by carnitine
would be expected to reduce the amount of activated AFB1 available for binding to DNA.
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This may be a very important mechanism by which camitine decreases the AFB 1-DNA
adduct concentration in the hepatocytes. Unfortunately,from this experiment we are
unable to differentiate the protein adducts formed with cellular protein and those formed
with added BSA.
GST activity

The present study found no significant e ffect ofcarnitine on GST activity toward
l-chloro- ,
2 4dinitrobenzene. This indicates that camitine has no influence on this
detoxification enzyme activity. Several dietary nutrients,nutritional status,drugs,and
xenobiotics have been demonstrated to a ffect GST activity. Vitamin A has been shown to
induce the activity of GST in liver fractions and thereby enhance the detoxification of
AFB 1 -epoxide (Bhattacharya et al. 198 9). However,no difference in the GST M l
protein concentrations was found in woodchuck hepatocytes treated with AFB 1 in the
presence or absence ofvitamin A (Yu et al. 19 9 4). Dietary restriction has been shown to
inhibit AFB 1-DNA adduct because ofinduction of GST activity toward AFB 1 -epoxide
(Chen et al. 19 9 5). Protein-deficient animals has lower GST activity and AFB 1-GSH
which resulted in higher AFB 1-DNA adduct formation (Mandell et al. 19 9 2).
Ethoxyquin, an antioxidant,added to the diet ( 0. 4%) and fed to rats inhibited
AFB 1 -DNA adduct formation because ofinduction of GST activity (Kensler et al. 1 98 9).
Another antioxidant,BHA, has been shown to increase the activity of GST,resulting in
the reduction ofDNA adduct formation (Monroe & Eaton, 198 7) . Oltipraz,a
chemotherapy drug,has been reported to induce GST activity,which leads to a reduction
ofputative preneoplastic lesions caused by AFB 1 (Primiano et al. 19 9 )5.In another study
the protective role of oltipraz has been shown to be a result of both inhibition of AFB 1
bioactivation and the induction of GS.T activity in human hepatocyte culture (Langouet et
al. 19 9 5). A traditional Chinese herbal drug,dimethyl- ,
4 '4dimethoxy- ,
5 ,
6 '5, 6'-
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dimethylenedioxy biphenyl-2, 2'-dicarboxylate (DDB), also has an inhibitory effect on
AFB1 binding to DNA. In this case, the effect is due to inhibition of cytocrome P-450
system by DDB, which results in the production of more hydroxylated metabolites which
are less genotoxic than the epoxide (Guengerich & Shimada 1991). A more recent study
has demonstrated a similar effect of DOB-mediated reduction of DNA adduct, where the
mode of action was through the induction of the GST activity and not the increased in the
production of hydroxylated AFB1 metabolites (Liu et al. 1995).
Total glutathione concentration
GSH is important in cellular defense mechanisms such as detoxification of reactive
xenobiotics and free radicals, and maintenance of immune function (Vina 1990). About
97.5 - 98.5% (Griffith 1988) or more than 99.5% (Anderson 1985) of the total glutathione
(oxidized + reduced glutathione) in tissues is in the form of reduced glutathione (GSH).
GSH can be formed from oxidised glutathione (GSSG) by the catalytic action of
glutathione reductase. Depletion of GSH concentration can be due to conjugation to
electrophiles (e.g. AFB1 -epoxide) or inhibition ofGSH synthesis. Low levels of GSH are
detrimental since that increases the susceptibility of cells to injury due to toxic attack.
The novel finding of the present study is the ability of camitine to prevent the
decrease in total glutathione content due to AFB 1 in the hepatocytes. This obseivation is
important since the availability ofGSH is essential for GST to promote AFB 1 -epoxide
binding to GSH and therefore spare binding to macromolecules. An increase in total
glutathione concentration may be indicative of reduced amounts of activated AFB1
formation in the presence of camitine. If camitine decreased the amount of AFBi 
epoxide, there would be decreased need of GSH for detoxification of the epoxide. It is
also possible that camitine induces the biosynthesis of glutathione. Additionally, camitine
itself may conjugate to the activated AFB 1 and therefore spare the glutathione. The data
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to support these hypotheses remain to be determined by additional experiments.
An anology to the camitine effect on AFB 1 -DNA adduct formation is the effect of
crocetin on the same. Crocetin, a carotenoid isolated from the seeds of Cape jasmine, has
been reported to decrease AFB 1 -DNA adduct production in both microsomal and cultured
cell systems treated with AFB 1 (Wang et al. 1991a). The crocetin concentrations ofO. l
and 0.5 mM decreased DNA binding by aproximately 17 to 38%, respectively. Crocetin
had no effect on AFB 1 -epoxide production in the microsomal system as quantified by
AFB 1 -8,9-dihydrodiol concentration. The protective effects of crocetin on DNA adduct
formation were related to its role in elevation of cytosolic GSH concentration and GST
activity. As for carnitine, it increased total glutathione concentration but had no effect on
GST activity.
The protective mechanism of geniposide, a compound isolated from the Rubiaceae
plant family, is different than that of crocetin. Geniposide decreased cellular GSH and
GSSG concentrations but induced the activity of of y-glutamyltranspeptidase (the rate
limiting enzyme for GSH synthesis) and GST (Wang et al. 1991b). Carbon tetrachloride,
bromobenzene, and acetaminophen have been found to deplete tissue levels of GSH (Reed
1994). In hepatocytes culture, acetominophen and AFB 1 both deplete GSH
concentrations (Hayes et al. 1986). In light of these observations, the GSH-sparing effect
of camitine is important and is a new function of camitine.
AFBI uptake by hepatocytes

This study found no significant difference in the uptake of AFB 1 by the hepatocytes
or their nuclei in the absence or presence of different concentrations of camitine.
However, it is possible that the dose response to carnitine was at the lower end of the
camitine concentration used in the experiments. This is because there was a steep decline
in the AFB 1 concentration between O and 200 µM camitine doses (FIGURE 3. 7).
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Additional experiments using O to 400 µM camitine with an increment of 50 µM need to
be carried out for clarification.

Conclusion
The results of this study lead us to conclude that carnitine enhances total
glutathione concentration and promotes the binding of activated AFB 1 to plasma albumin,
and that it therefore spares DNA from covalently binding to the activated AFB 1 .
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CHAPTER 4

Effects of L-Carnitine on Aflatoxin B 1 Bindings to Exogenous DNA and Proteins

Introduction

Aflatoxins, a group of secondary metabolites ofAspergillus.flavus and A.
parasiticus, are commonly found to contaminate food and feed supplies. Consumptions of
aflatoxins contaminated food have been linked to incidences of human liver cancer (Alpert
1 97 1 ; Yu 1995). Due to mounting evidence, the International Agency for Research on
Cancer (IARC) has upgraded AFB1 from a Group II to a Group I human carcinogen in
1993 (IARC 1 993).
Aflatoxin B1 (AFB1 ) is the most toxic and carcinogenic of all naturally occuring
aflatoxins. Its metabolite, AFB1 -epoxide, possesses hepatocarcinogenic and hepatotoxic
properties through its ability to covalently bind to cellular DNA and protein respectively.
The AFB1 -DNA adducts formation is a crucial step for AFBi -induced carcinogenesis. The
DNA adducts concentrations have been correlated to incidences of liver cancer in animals
(Bechtel 1989) and humans (Groopman et al. 1 988).
L-Carnitine, 3-hydroxy-4-N-trimethylamino butyric acid, is an important co-factor
for mitochondrial long chain fatty acid oxidation. We have reported that camitine
supplement reduced the AFB1 binding to liver DNA and RNA, 6-h after a single oral dose
of AFBi , in intact rats (Sachan & Yatim 1 992). Carnitine has no effect on AFB1 -protein
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adducts formation in the liver. In isolated hepatocytes, increasing concentrations of
carnitine linearly decreased the binding of AFB 1 to DNA (Chapter 3). Therefore, one of
the objectives of this study was to determine if the effects of carnitine on AFB i -DNA
adduct formation were a result of microsomal metabolism of AFB 1 • Since microsomes
contain the enzymes that bioactivate AFB 1 , the findings of this study were expected to
elucidate the mechanisms of carnitine-mediated decrease of AFB 1 -DNA adduct formation.
Furthermore, it was deemed necessary to determine the specificity of carnitine effect by
testing the effect of carnitine analog (acetylcarnitine), and carnitine-like substances,
(choline and glycine) on AFB 1 -DNA adducts formation in microsomal systems.
We had observed that the total amounts of AFB i , 6-h post-dosage, present in the
liver and kidney were not significantly different between the carnitine supplemented and
control animals. (Table 2.3). However, the concentration of AFB 1 was higher in the
plasma of carnitine supplemented rats. Further, carnitine ameliorated the earlier signs of
acute toxic effects of AFB i , such as the increase in total lipids concentrations in the liver
and the decrease in total lipids and triacylglycerol concentrations in the plasma (Sachan &
Yatim 1992). The higher amounts of AFB 1 in the plasma of carnitine supplemented rats
were interpreted to indicate that carnitine may inhibit the uptake of AFB 1 into the
hepatocytes.
AFB 1 can readily bind to plasma albumin once it is absorbed from the small
intestine, and that albumin serves as a major transporter of AFB 1 in blood (Dirr & Scabort
1987). Since it has been postulated that some bioactivation of AFB 1 occurs in the
intestinal mucosa (Hartiala 1977; Vainio & Hietanen 1979) and blood (Sabbioni et al.
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1987), albumin could be expected to bind to metabolites of AFB1 as well. The binding of
AFB 1 to albumin after being absorbed has been postulated to be one of the detoxicification
processes of AFB 1 (Hseih & Wong 1994). It was hypothesized, therefore, that carnitine
may increase the binding of AFB 1 to proteins in the mesentric veins and portal vein blood,
resulting in decreased availability of AFB 1 and its metabolites to bind to hepatocellular
components. Therefore, the other objectives of this study were to determine the effects of
camitine on binding of AFB 1 to plasma proteins and bovine serum albumin with and
without microsome.

Materials and Methods

Animals

The research protocol was approved by the Animal Care and Use Committee of
the University of Tennessee, Knoxville. Male Sprague Dawley rats weighing 300-350 g
were individually housed in suspended stainless steel cages in a cubicle of an AAALAC
approved animal facility. The animals were given free access to Teklad 22/5 Rodent Diet
(W) 8640 (Harlan, Indianapolis, IN) and water.

Liver Pe,fusion and Microsome Preparation

Rats were anesthetized with metofane (Pitman-Moore, Inc. Mundelein, IL) by the
open-drop method in a closed jar. The portal vein was cannulated and and the liver was
perfused with 100 ml ice-cold physiological saline. The details of the procedure are
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described in Appendix 8. The perfused liver was mixed with 0. 1 54 M KCl buffer
containing 0.0 1 M KH2P04 (pH 7.4) and homogenized with 3 complete strokes in a teflon
glass homogenizer to produce a 25% (w/v) homogenate. The homogenate was
centrifuged at 1 0,000 x g for 20 min at 4 °C. The supernatant was centrifuged at 1 00,000
x g for 60 min at 4 °C using a Sorvall ultracentrifuge. The microsomal pellet was
suspended in glycerol:phosphate buffer ( 1 : 1 , glycerol: 0 . 1 5 M KH2PO4 (pH 7. 4).
Microsomal protein concentration was determined by the method of Lowry et al. ( 1 95 1 )
decribed in Appendix 5.
fHJAFB1 Binding to Calf Thymus DNA
The DNA binding method of Allameh et al. ( 1 988) with modifications (Hasler et
al. 1 994) was followed (Appendix 9). There were four groups in this experiment, Group
1 had no microsome and no carnitine; Group 2 had no microsome but had carnitine ( 1 .2
mM); Group 3 had microsome but no carnitine; and Group 4 had both microsome and

carnitine. Briefly, the microsomal incubation mixtures contained 0. 1 M phosphate buffer,
microsome equivalent to 1 . 0 mg protein, 1 .2 mM L-camitine or other tested compounds
(pH 7.0), 2 M NADPH, 2 nmol [3H]AFB1 dissolved in dimethylsulfoxide (DMSO), 0. 1 mg
calf thymus DNA, and double deionized water (DOW) to make-up a total volume of 1. 0
ml The samples were incubated at 37 °c for 30 min in triplicates and repeated 5 times
using freshly prepared microsome from a rat each time.
At the end of the incubation time, a volume of 5 M NaCl was added to produce a
mixture containing 1 M NaCl. Two ml of chloroform:isoamyl alcohol (24: 1, v/v) and 0.9
mg of calf thymus DNA ( as a carrier) were added. The tubes were shaken and
centrifuged at 1 0,000 x g for 1 0 min. The DNA fraction (top layer) was again extracted
with chloroform:isoamyl alcohol, shaken and centrifuged 1 0,000 x g for 1 0 min. The
DNA fraction was centrifuged at 1 00,000 x g for 1 h. The supernatant was mixed with an
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equal volume of95% ethanol and centrifuged at 10,000 x g for I O min to pellet the DNA.
The DNA pellet was resuspended in 1 ml of O. l M NaCl (pH 7.0). The DNA
concentration was determined colorimetrically according to Ceriotti (1952), Appendix 4.
An aliquot of200 µl of DNA solution was added to 5 ml Aquasol-2 (Dupont-NEN
Research Products, Boston, MA), and DPM were determined for 10 min in a liquid
scintillation counter (LS-3801 Beckman Instrument, Irving, CA).
{3H]AFB1 Binding to Bovine Serum Albumin
For this study, similar incubation medium and experimental design were used
as in the AFB 1 -exogenous DNA adducts formation as described above except that fatty
acid free bovine serum albumin (BSA) was added in placed of DNA. In brief, after
incubation, the mixtures were quickly chilled in an ice-water bath and then centrifuged at
100,000 x g for 1 h at 4 °C to pellet the microsome. The supernatant was extracted with 2
ml chloroform:ethylacetate (1: 1, v/v), and centrifuged at 2,000 x g at 4 °C for 10 min to
remove free AFB 1 • The aqueous (top layer) was transferred to new tubes and extracted
with chloroform: ethylacetate one more time. Protein concentrations were determined in
the aqueous (protein) fraction according to Lowry et al. (195 1) method. Radioactivity or
DPM was measured by adding 0.2 ml of the protein fraction in 5 ml Aquasol-2 (Dupont
NEN Research Products, Boston, MA), with 0.04 ml of glacial acetic acid to decrease
random coincidence monitor (RCM).
[3HJAFB1 Binding to Microsome
The incubation medium and procedure were similar to that used in the AFB1
binding to BSA described above. There were two groups in this experiment, control and
carnitine groups. The medium contained O. 1 M phosphate buffer, microsome equivalent
to 1.0 mg protein, 1.2 mM L-carnitine (pH 7.0) for the carnitine group, 2 M NADPH, 2
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nmol [3H]AFB 1 dissolved in climethysulfoxide (DMSO), and DDW to make-up a total
volume of 1 . 0 ml.
At the end of the incubation period, the mixture was quickly chilled in an ice-water
bath and centrifuged at 100,000 x g for 1 h at 4 °C to pellet the microsome. The
supemant was removed, and the microsomes were then suspended in 1 ml of 1 M KOH.
The microsomal suspension was extracted with 2 ml chloroform:ethylacetate (1 : 1 , v/v),
and centrifuged at 2,000 x g for 1 0 min to remove free AFB 1 . The top (aqueous layer)
was transferred to new tubes and extracted with chloroform: ethylacetate one more time.
Protein concentration and radioactivity were measured as described in the earlier
experiments.
AFB1 Non-Covalent Binding to Proteins as Measured by Membrane Ultra.filtration
Method
The incubation was done in glass culture tubes. The mixture contained BSA (0.8
µg) or rat plasma (20 µI equivalent to 0.8 µg albumin}, with or without 1 .2 mM L
camitine (pH7.0}, 2 nmol [3H]AFB 1 dissolved in DMSO and was made-up to a total
volume of 300 µI with DDW. The mixture was allowed to stand at room temperature
(approximately 25 °C) for 1 0 min and then transferred into the upper chamber of a
prewashed Ultrafree-MC filter unit (Millipore Corporation, Bedford, MA). The nominal
molecular weight limit of the Ultrafree-MC regenerated cellulose membrane used was
30,000. Refer to Figure 4.1 for the flow diagram of separation of bound versus unbound
[

3

H]AFB 1 to proteins by the modified method ofLipford et al. (1 990). The filter unit was

then centrifuged at 2000 x g for 20 min. The filtrate was removed, and the concentrate in
the upper chamber was washed once with 400 µI Hank's buffer and centrifuged again at
2000 µI for 30 min. The upper chamber that retained the protein was transferred into
scintillation vials and radioactivity was determined.
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Prewashed Ultrafree filter with 400 µI DDW

Transfer incubation mixture to top chamber of
Ultrafree filter unit
Centrifuge at 2,000 x g for 20 min at 25 °c

Top chamber
(400 µI limit)

Protein
Concentrate

Membrane

Filtrate
Remove filtrate

Add 400 µI of buffer to top chamber
Centrifuge at 2,000 x g for 30 min at 25 °c
Measure radioactivity in the top chamber that
contains the protein concentrate

FIGURE 4.1 Ultrafihration method of determining bound PH]AFB 1
to proteins
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Statistics
The values are reported as means ± SEM. Statistical analysis of the data was
performed using the SAS statistical program (SAS version 6. 1 1 , SAS Institute Inc., Cary,
NC). The differences between two groups were analyzed by Student's t test. For
comparison of several groups, general linear model (GLM) procedures or two-way
crossed ANOVA were used when appropriate. When significant, Duncan's Multiple Range
test or Contrast statement were used to compare between means. The critical level of
significance was set at p < 0. 05.
Results

AFB1-calf thymus DNA adductsformation
The bindings of AFB 1 to calf thymus DNA in the presence or absence of carnitine
and microsome are shown in Figure 4.2. There were none or very little AFB1 -DNA
adducts formed in the absence of microsome in the incubation mixture, and carnitine has
no significant effect. In the presence of microsome, there was significantly higher AFB 1 DNA adducts formation in the control (250 pmol/mg DNA) and carnitine (200 pmol/mg
DNA) groups. This is consistent with the fact that AFB 1 has to be metabolized for it to
bind to DNA. This microsome-mediated AFB 1 binding to DNA was significantly lower in
the presence of carnitine. This indicates that carnitine may alter the bioactivation of AFB 1
(produces less epoxide) and/or affect the binding of AFB 1-epoxide to DNA (inhibition of
AFB 1 -epoxide electrophilic binding to guanine of DNA).

300

-

250

z

<(

c 200

a

I

I

I
I

L
I

T

I

b

D Control
II L-Carnitine

E 1 50

z

<(

q
<(

1 00
50
C

0

C

- Microsome
Group

+ Microsome

FIGURE 4.2 Effects of L-carnitine (1 .2 mM) on AFB1 -calf thymus DNA adducts formation
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Specificity of camitine

The effects ofcarnitine, acetylcarnitine, and carnitine-like substances on the DNA
adducts formation are shown in Figure 4.3. The concentration ofAFB 1 -DNA adducts in
the control group was 2 16 pmol/mg DNA. In the camitine, acetylcamitine, and GABA
groups, the DNA adduct concentrations were 170, 154, and 165 pmol/mg DNA
respectively. The decreases in DNA adduct in these three groups were significantly lower
than the control group. This shows that the reduction in the DNA-adducts formation is
not very specific to carnitine. Choline and glycine had no significant effect on the AFB i 
DNA adduct formation.

AFB1-BSA Adducts Formation

The binding ofAFB 1 to proteins (BSA and microsomal protein) are presented in
Figure 4.4. In contrast to DNA (Figure 4.2), there was some binding ofunmetabolized
AFB 1 to BSA (13.4 pmol/mg BSA in Group 1, and 16.2 pmol/mg BSA in Group 2).
These are noncovalent bindings since no microsome was added into the incubation mixture
to produce the AFB 1-epoxide that can bind covalently to macromolecules. Camitine had
no significant effect (contrast p value = 0 . 171) on these non-covalent AFB 1 -B SA bindings
(Group 1 vs Group 2).
In the presence ofmicrosome, there were markedly higher amounts of AFB 1 -BSA
adduct formed (Group 3 and 4). The BSA adducts formed were 5.8 times higher in
Group 3 than in Group 1, and 5.5 times higher in Group 4 than in Group 2. The higher
concentrations ofAFB-BSA adducts in the presence of microsome were due to both
covalent and non-covalent bindings. The average amount ofcovalent AFB 1 -BSA bindings
in Group 3 was 64. 1 pmol/mg BSA, and in Group 4 was 72. 7 pmol/mg BSA (calculated
by subtracting the adduct concentrations ofGroup 3 from Group 1, and Group 4 from 2).
Therefore, covalent bindings constitute the higher portion ofthe AFB 1 -BSA adduct shown
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in Groups 3 and 4. The presence of camitine in the microsome-containing incubation
mixture significantly increased (p = 0.0005) the AFB1 -BSA adducts formation (Group 4 vs
Group 3). This is an indication that camitine increased the covalent binding of AFBi 
epoxide to BSA.
AFBrMicrosoma/ Binding
The concentrations of AFB1 binding to microsomal proteins in the absence or
presence of camitine are shown in Figure 4.5. Obviously, there was some binding of
AFB1 to the microsomal component, and camitine significantly increased (p = 0. 007) the
binding compared to the control. This AFB 1 binding to microsomal protein was about
two times higher than the binding of AFB1 to BSA (Figure 4.4; Groups I and 2).
AFB1 Non-Covalent Binding to Proteins as Measured by Ultrafiltration Method
The data on the binding of unmetabolized AFB1 to plasma proteins and BSA are
presented in Figures 4.6 and 4.7, respectively. The camitin_e group had significantly
higher binding of AFB1 to plasma proteins than the control group (p = 0.022). The AFBi 
BSA adducts formation was also higher in the camitine group than the control group (p =
0.01 8). Compared to the rat plasma, higher concentrations of the protein adducts were
formed (approximately 1 59°/c, more in the control groups and 1 75% more in the carnitine
groups) when the protein was BSA. This is most likely related to the purity ofBSA
protein as plasma has components other than albumin.

Discussion

The experiments in this Chapter were aimed exploring other possible mechanisms
of camitine-mediated attenuation of AFBi -DNA adduct formation. The data suggest that
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at least three processes are affected by carnitine. These are: I ) bioactivation of AFB 1 and
binding of activated AFB 1 to DNA; 2) binding of AFB 1 to plasma proteins; and 3)
binding of AFB 1 to microsomal proteins.

Bioactivation ofAFB1 and binding of activated AFB1 to DNA
AFB 1 needs to be activated by microsomal enzymes to form the AFB 1 -epoxide
which covalently binds to the electrophilic center (N, 0, and S atoms) of cellular
macromolecules such as DNA, RNA, and protein (Stark 1 986). The covalent binding,
especially to DNA, is the crucial initial step of AFB 1 carcinogenesis.
First of all, the current study, confirms the role of microsomal enzymes in
producing the metabolites that can bind to DNA. More importantly, this study shows that
in the presence of camitine, the binding of microsomal activated AFB 1 to DNA was
decreased. This indicates that carnitine interferes with the bioactivation of AFB 1 .
Microsomes contain the enzymes that biotransformed AFB 1 to its activated form (AFB i 
epoxide) and the less toxic hydroxylated metabolites. Therefore, if camitine can affect the
metabolism of AFB 1 that results in lesser production of AFB 1 -epoxide, then there will be
lower amount of epoxide for covalent binding to DNA. On the other hand, it may be that
camitine has no effect on the metabolism of AFB 1 whatsoever, but it simply prevents the
epoxide produced from binding to DNA. This postulation is made on the basis that
camitine itself may bind the AFB 1 -epoxide and therefore limit the amount of epoxide for
binding to DNA. Carnitine has the quartemary nitrogen group similar to the electrophilic
center of guanine of DNA and is available for electrophilic attack by AFB 1 -epoxide. More
studies are needed to specify which one of the above two pathways is operational.
The effect of camitine is not highly specific as acetylcamitine and GABA were
also found to reduce the AFB 1 -DNA adduct formation to about the same degree as
carnitine. Two other compounds structurally related to camitine, choline and glycine, had

85
no significant effect on the binding of AFB 1 -epoxide to DNA. The analogy with GABA in
this regard is quite interesting for studying the receptor-mediated mechanism of camitine
effect.
The lack of choline effect is not entirely surprising as choline effect is highly
controversial. It has been reported that choline-deficiency had no effect on the liver
AFB 1 -DNA adduct concentration in rats given a single dose of AFB1 . However, when
multiple doses of AFB 1 were given, the DNA adduct formation was markedly elevated in
the choline-deficient animals (Schrager et al. 1990). On the contrary, an earlier report
indicates that a diet marginally deficient in lipotropes (methionine, choline, and folacin) fed
to rats which were given a single dose of AFB 1 suppressed DNA adduct formation in the
liver (Campbell et al. 1978). Yet another recent study demonstrated that a choline
methionine deficient diet, fed to rats, had no significant effects on serum biochemical
parameters and liver pathology due to a dose of AFB 1 (Mehta et al. 1993).
Binding ofAFB1 to proteins
AFB 1 and its metabolites, particularly AFB 1 -epoxide, are known to bind to plasma
protein (Chu 1994), and this binding may be altered by pH and fatty acid concentrations
(Dirr 1989). Camitine significantly increased the covalent binding of microsomal activated
AFB1 to BSA, a purified form of serum protein (FIGURE 4.4). It also increased the
binding of non-metabolized AFB1 to BSA and plasma proteins (FIGURES 4.6 and 4.7).
The binding of AFB 1 was nearly six times higher in the presence of microsome than in
absence of microsome, suggesting that AFB1 metabolites have a higher affinity for BSA
and that the effect of carnitine is significant in both cases.
There are two hypotheses for how camitine elevation of AFB 1 -protein binding can
lead to a reduction in AFB 1 -DNA binding. First, it is postulated that if carnitine can
somehow increase the AFB1 retention by plasma proteins, less will be available for uptake
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by hepatocytes. When the uptake of AFB 1 is reduced, less AFB 1 will be ·available for
metabolism in the liver cells to cause harmful physiological changes. It has been suggested
that since the liver has high capability to draw free AFB 1 from the blood, AFB 1 binding to
plasma albumin once it is absorbed from the intestine can be one of the detoxification
processes of AFB 1 (Hsieh & Wong 1994). Plasma contains about 7-8% proteins, and
albumin constitutes about 50-60% of plasma proteins (Anderson & Lunden 1979).
Albumin has been shown to be the main plasma protein that binds AFB 1 and therefore to
serve as the major transporter of AFB 1 in the blood (Dirr & Schabort 1987). It was
demonstrated that almost all (> 95%) of the AFB 1 found in rat plasma proteins was
noncovalently bound, and about 800/o of AFB 1 was found in the albumin fraction
(Ewaskiewicz et al. 199 1). So the albumin serves as the transporter of AFB 1 in the
plasma, and carnitine is a positive effector.
Second, since carnitine increases the covalent binding of AFB 1 to plasma protein,
it is possible that carnitine can also increase the covalent binding of AFB 1 to cellular
protein and therefore reduce the binding of activated AFB 1 to cellular DNA. We were
unable to study this for technical reasons.
The above AFB 1 -albumin data raise an important implication, since AFB 1 -albumin
adduct concentration in plasma has been widely used as an acceptable biomarker in
evaluating exposure of AFB 1 in humans (Chang et al. 1 994). Our :findings invoke a special
caution that should be taken when interpretating the results of AFB i -albumin data. Higher
concentrations of AFB 1-albumin adduct in the blood may not always indicate higher intake
of AFB 1 but may be a consequence of modulation by dietary nutrients such as camitine
and others yet to be identified. Dirr (1987) reported that the increase in plasma
concentrations of long chain fatty acids considerably increased the AFB 1 -plasma albumin
concentration. This is besides the fact that AFB 1 binds to serum albumin and hepatic
DNA in a dose-dependent manner (Sabbioni et al. 1990).
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Binding ofAFB1 to microsomal proteins
From this rather indirect determination, it is extrapolated that carnitine increases
binding of AFB 1 to the microsome. This is supported by the fact that AFB1 has been
shown to have highest affinity for liver microsoine followed by the cytosol, mitochondria
and nuclei (Ewaskiewicz et al. 1991).
Conclusion
The protective mechanisms of carnitine against the AFB 1 -DNA adduct formation
are related to 1) reduction of AFB 1 bioactivation; 2) sequestration of AFB 1-epoxide; and
3) enhancing of the binding of AFB 1-epoxide to cellular protein and microsome.

88

CHAPTER S

Future Research

The following are some areas for future studies:
a) Identify the cytochrome P-4 50 isozyme(s) and quantify the metabolites of AFB 1
that may be affected by carnitine. These findings will show if carnitine has an
effect on AFB 1 metabolism, especially the production of the AFB 1 -epox:ide.
b) Determine if carnitine can bind to activated AFB 1 • The results of this
experiment will further explain the mechanisms of carnitine reducing the AFB 1 DNA adduct formation.
c) Determine the effect ofcarnitine on AFB 1-glutathione conjugate formatio�
concentrations ofGSH and GSSH, and GSH:GSSH ratio. These data will
explain how carnitine ameliorated the reduction in total glutathione
concentration caused by AFB 1 .
d) Determine the effect of camitine on the AFB 1 binding kinetics (for examples,
maximum number ofbinding sites (Bmax) and equilibrium dissociation constant
(Kd)) to plasma protein (albumin) and cytosolic protein.
e) Determine the effect of carnitine on the bindings of AFB 1 to DNA, RNA, and
protein when the macromolecules are incubated together in a microsomal
system. This will provide information about the changes in the binding affinity
of activated AFB 1 to macromolecules in presence of carnitine.
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APPENDIX 1
Isolation and Preparation of Hepatocytes
Buffersfor Pre-Perfusion, Perfusion and Incubation
Table I shows the buffers used for preperfusion, collagenase perfusion and
incubation. The buffers were modified Hank's balanced salt solutions as described by
Lotlikar et al. (1 989). The pre-perfusion modified Hank's buffer contained 0.5 mM
EGTA, 25 mM HEPES, and 0. 5% BSA (added prior to perfusion) but had no ca++ and
Mg++. The solution was saturated with 95% 02 + 5 CO2% gas before used. The
perfusion buffer contained modified Hank's buffer having 2 mM CaC12, 0.5 mM EGTA,
25 mM HEPES, 0.5% BSA, and 0.05% collagenase (type IV). The solution was
saturated with 95% 02 + 5 CO2% gas before the addition of BSA and collagenase just
prior to perfusion. The incubation buffer was similar to the collagenase buffer except it
had no collagenase.

Perfusion Apparatus
The perfusion apparatus utilized were similar to that described by Seglen (1 976).
It consisted of :
a) a water-jacketed coiled glass tube (2 x 4 mm glass tube with 22-24 coil (coil diameter
30 mm; coil length 100mm) connected to a water bath that maintained the buffer
temperature at 37 ° C.
b) a filter and bubble trapping unit that prevented any bubbles from entering the liver
during perfusion.
c) an adjustable flow pump unit that pumped the buffer from the buffer flask through the
coiled glass tube and flowed into the filter and bubble trapping at certain flow rate.
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d) a canula tube that connected to the filter and bubble trapping unit.

Table I The compositions of the buffers were as follows :
++

Chemicals

ca

(mw'L)

Mg++-free

_ and

10% BSA (ml/L)
Collagenase
Needed (mVperfusion)

'

Incubation

buffer

buffer
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60
1000
190
5,958
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-
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buffer
CaCl,
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KCl
KH)P04
NaHCO�
NaCl
N�HP04.H') O
Glucose
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HEPES
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e) a 95% 02 and 5% CO2 gas tank.

Surgery and Perfusion Procedure
a) Rat was anesthetized with metofane (Pitman-Moore, Inc. Mundelein, IL) by open-drop
method in a closed jar.
b) The anesthetized rat was placed on an operating tray on its back. When needed,
metofane in a 10 ml scintillation glass bottle was placed to cover the nose of the
rats to continue anesthesia of the rat.
c) A cut was made from the middle of lower end of the abdomen to the upper end of the
abdomen just below the diaphragm.
d) A V-shaped cut was made below the ribs that went to the left and right ribs.
e) The intestine was carefully moved to the left side of the abdomen to exposed the portal
vem.
t) Two loose ligatures (about 5 mm apart) were placed around the portal vein about 1-2
mm away from the liver.
g) The Ca++- and Mg++-free buffer was tum on at a flow rate of 30 ml/min. This buffer
was continually saturated with 02 gas and the temperature were set at 37 °C.
h) A small cut was made just below the furthest ligature from the liver, cannula tube (with
the buffer flowing) was inserted through the cut, and the ligatures were tightened.
i) The perfusion flow was increased to 50 ml/min and the posterior vena cava was cut to

109
the let the perfusate to escape.
j) After about 2-3 min, while the perfusate still flowing the liver was removed from the rat
by cutting all the attachments to the liver and placed flat as the in situ position on
a perfusion dish.
k) When the 500 ml of Ca++-free buffer was about finished (10 min.), the buffer flow was
stopped, changed the buffer reservoir to the collagenase buffer in a 250 ml beaker,
placed the liver dish on top of the 250 ml beaker, and started the buffer flow at 50
ml/min for about IO min. The liver swelled to about twice its original size.
l) The liver was placed on a watch glass, added with 5 ml of the incubation buffer
containing 0.5% BSA, and the liver was carefully raked with a stainless steel fork
to release the cells from the connective tissue and vascular stroma.

Cell Purification and Viability Test
a) The liberated cells were suspended in IO ml of ice-cold incubation buffer containing
0.5% BSA, and was centrifuged at 50 x g for 3 min at 4 °C. The loose cells and
supernatant were removed. After this time, the cells were placed in a ice-bucket
(temperature at about 4 °C) when they were not being manipulated.
b) The heavy cell pellet was resuspended with 20 ml of incubation buffer containing O. 5%
BSA, and centrifuged as above. The supernatant and loose cells were discarded.
c) Step 4 b was repeated 2 more times to ensure maximal removal of dead cells and other
cells (macrophage and fat cells).
d) The hepatocytes pellet was suspended and made-up to 20 ml suspension with the
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incubation buffer containing 0.5% BSA
e) For viability test, the hepatocyte suspension was diluted 1 : 10, and I 00 ml ofthis diluted
cells was addded to I 00 ml of O. 6% trypan blue (therefore, the dilution factor
=20). The cells were counted from 4 outer squares in a hemacytometer, by an
Olympus T04 1 microsope.
t) Calculation:
Cells/ml = Average # cell x D.F. x Factor for vol. of cell suspension under cover slip
(10-4 ml)

:. Cells/ml = (Total # cells/4) x 20 x 104/ml.
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APPENDIX 2

Composition of Hepatocyte Incubation Mixtures and Detemination of AFB 1Macromolecule Adducts Formation

A. Incubation Mixture (in duplicate or triplicate)

GrQJ.112 I
O CNE

I

2

4

GrQYl2 2 ' Groug 3
0.2 mM 0.8 mM

GrQU12

CNE

CNE

CNE

CNE

2

2

Groug 5

1 .2 mM : l . 5 mM

IO x I 06 cell/ml, ml

2

2

2

L-Carnitine ( I 0

--

1 00

400

600

750

2 130

2 130

2 1 30

2130

2 1 30

i,

l

mM,
pH 7.0), µI
3

Hank's Buffer
(+ 0.5%BSA), µI

4

DOW, µl

750

650

350

1 50

0

5

DMSO, µI

1 00

1 00

1 00

1 00

1 00

6

[H ]AFB1

20

20

20

20

20

5

5

5

5

5

3

(0. l mCi/umol), µl
TOTAL, ml

I

I

B. Incubation Procedures
I.

Add hepatocytes, L-camitine, HB, and DOW (but not DMSO and [H3]AFB1) in 25

11 2
ml Erlenmeyer flasks.
2.

Mix the mixtures by swirling the flasks.

3. Flush the flasks (without touching the incubation mixture) with 02:C02 (95%: 5%) for
30 sec, and seal with rubber stoppers.
4.

Incubate at 37 °C for 10 min a shaking water bath (speed 75-80 rpm which is about
3 . 5 of the water bath knob scale).

5. Mix [H3] AFB 1 and DMSO together, and add them to the incubation mixture.
6.

Mix by swirling the flask.

7.

Flush the flasks (without touching the incubation mixture) with 02 :C02 (95%:5%) for
1 min, and seal with stopper.

8. Incubate at 37 °C for 60 min in a shaking water bath (speed 75-80 rpm).
9. Place the flasks immediately into an ice-water bath to stop the reaction.
1 0. Transfer 100 µI ofTh1 into microcentrifuge tubes containing 1 00 µl of 10 mM HCl for

Total GSH determination, 0.5 ml into another tubes for GST activity assay ( 2 x 1 06
cells contain 5-8 mg protein; needed 1 mg protein), 3 ml into another tubes for DNA
determination, and 300 µI into another tube for polar and non-polar metabolites
extraction and quantitation. Transfer also the remaining of IM into new tubes.
11. Quickly freeze all tubes in liquid nitrogen, and store tubes at -80 °C until use.

C. Macromolecules Extraction, Quantitation, and AFBrmacromolecules Determination
1 . Centrifuge the tubes (from step B 1 0) at 500 x g for 5 min to sediment cells. Discard

SN.
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2. Wash the cells with 1 ml of ice-cold incubation buffer (no BSA). Suspend cells by
gentle mixing. Centrifuge. Discard SN.
3. Repeat step 2.
4. Resuspend cell in 4 ml of incubation buffer.
5. Homogenized cells with 3 complte strokes in a teflon-glass homogenizer.
6. Transfer 3 ml of homogenized cells and add 3 ml ofice-cold 1.0 PCA.
7. Vortex and centrifuge at 600 x g for 10 min at 2 °C. Discard the supernatant.
8. Wash pellet with 1.5 ml 0.2N PCA and centrifuge at 600 x g for 10 min. Remove
supernatant.
9. Repeat Step 8 for 3 more times.
1 1. Add 1. 5 ml O. 1 N KAc prepared in absolute ethanol. Vortex, centrifuge at 2000 x g
and discard supernatant
12. Add 1. O ml chloroform: absolute ethanol ( 1: 1, v/v). Vortex, centrifuge at 2000 x g
and discard supernatant. Repeat once.
13. Add 1 ml absolute ethanol. Vortex, centrifuge at 2000 x g and discard supernatant
completely. Air dry or vacuum dry the pellet.
14. Add 1. 0 ml of 1. SN PCA, resuspend pellet by vortexing, and leave overnight in
refrigerator (4 °C).
15. Centrifuge at 2000 x g, collect supernatant.
16. Wash pellet 2 times with 0.5 ml of0.5N PCA. Vortex, centrifuge, and pool
supernatant each time into Step 15 tubes. The combined supernatants contain the
RNA fraction.
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17. Add 1 ml of O. SN PCA to pellet. Vortex and incubate at 70 °c water bath for 20 min.
Centrifuge and collect supernatant.
1 8. Repeat Step 1 8. The combined supernatant contains the DNA fraction.

19. Wash pellet with DOW twice.
20. Add 1.0 ml of I .ON KOH to pellet. Vortex and incubate at 70 °C water bath for 15
min. Centrifuge and collect supernatant. The supernatant contains the protein
fraction.

2 1. RNA is determined the same day spectrophometrically at 260 run using yeast RNA as
standard.

22. DNA is determined by Ceriotti method (1952) (APPENDIX 4 ).
23. Protein is determined by Lowry et al. (195 1) (APPENDIX 5).
24. To measure radioactivity, transfer 0. 5 ml of each RNA, DNA, and protein fractions
into scintillation vials, add 5 ml of scintillation fluid. For protein samples, add 0. 1ml
glacial acetic acid. Mix by turning vials, and count radioactivity (DPM) for 10 min.
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APPEND1X 3

DNA Extraction and Isolation (Genomic DNA Procedure), Quantitation, and
AFB 1-DNA Determination

1. At the end of incubation time, centrifuge the tubes at 500 x g for 5 min to sediment
cells. Discard SN.
2. Wash the cells with ice-cold 1ml of Hank's buffer (no BSA). Suspend cells by gentle
mixing. Centrifuge. Discard SN.
3. Repeat step 2.
4. Add 0.3 ml digestion buffer (100 mM NaCl, 10 mM Tris-Cl (pH 8.0), 25 mM EDTA,
pH 8.0, 0.5% SOS, and added fresh 0. 1 mg/ml proteinase K) to pellet. Suspend cells
by gentle mixing. Tightly cap tubes.
5. Incubate at 50°C in a shaking water-bath for 12-18h (80-90 oscillations/min).
6. Add 0.3 ml digestion buffer (without proteinase K), and mix.
7. Add 0.6 ml of phenol:chloroform:isoamyl alchohol (25:24: I) to extract DNA.
8. Vortex, centrifuge at 1700 x g for 10 min.
9. Transfer 500 ul of the top ( aqueous) layer to new tubes.
10. Add 250 ul of3.0 M sodium acetate and 1000 ul of 100% alcohol. Vortex.
1 1. Centrifuge at 1700 x g for 2 min. Discard SN.
12. Wash pellet thoroughly with 1 ml of 70% EtOH. Centrifuge at 1700 x g for 2 min.
Discard SN. Dry in a 'Speedvac Concentrator' for 1 min.
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13. Suspend DNA pellet in 1 ml of 10 mM Tris-Cl (pH 7.4) containing lmM EDTA (TE
buffer) until dissolve.
14. Remove RNA by adding 0.1% SOS (10 ul of 10 % SOS) and 1 ug/ml DNAase-free
RNase (20 ul of 50 ug/ml RNase), and incubate at 37 °C for 1 h.
15. Add 1 ml of chloroform:isoamyl alchohol (10:2), mix thoroughly.
16. Centrifuge at 1700 x g for 10 min. Transfer 800 ul of the top layer (aqueous layer)
into new tubes.
17. Add 400 ul of 3M sodium acetate and 1.6 ml 1000/o EtOH. Vortex. Centrifuge at
1700 x g for 2 min. Discard the SN.
18. Wash pellet thoroughly with 1 ml of 70% EtOH. Centrifuge at 1700 x g for 2 min.
Discard SN. Dry in a 'Speedvac Concentrator' for 1 min.
19. Resuspend DNA in 1 ml of 10 mM Tris-Cl (pH 7.4) containing l mM EDTA.
(DNA may be shaken gently at R. T. or at 65 °C for several h to aid solubilization)...
20. Determine DNA content spectrophotometrically using calf thymus DNA dissolved in
Tris-EDTA buffer as standards (0.2 to 5 ug/ml) and by Ceriotti method (APPENDIX
4 ).
(Concentration of DNA is approximately 2 mg/g of cells; I g of hepatocytes contain
approximately 109 cells)
21. Transfer 0.2 ml of pure DNA extracts into scintillation vials, add 5 ml scintillation
fluid, and measure radioactivity (DPM) for 10 min.
22. Store DNA at 4 °C for short-term storage, and at -80°C for long term storage.
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APPENDIX 4

DNA Assay

Procedures:
1 . Set the DNA standards and sample tubes as shown below:
Tube

1

ms/ml DNA TE Buffer

o 04% Indole

c HCI

CHCli

mgDNA

Blank 0 µI

1000 ul

0.5 ml

0.5 ml

2 ml

0

SI

5

995

0.5

0.5

2

5

S2

10

990

0. 5

0.5

2

IO

S3

15

985

0.5

0.5

2

15

S4

20

980

0.5

0.5

2

20

S5

25

975

0.5

0.5

2

25

S6

30

970

0.5

0.5

2

30

800-900

0.5

0.5

2

?

980

0. 5

0.5

2

?

Sample 1 00-200 µl
Sample

20 µl

2. Add DNA standards or sample, TE buffer (see APPENDIX 4), and 0.5 ml of 0.04%
indole. Mix.3 . Add 0.5 ml concentrated HCI. Mix.
4. Cover tunes with cap tightly and place in 1 00 ° C water-bath for exactly 1 0 min.
5. Immediately cool tubes by dipping them in a bucket of tap water.
6. Add chloroform (do this under the hood) and vortex thoroughly.
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7. Centrifuge at 1 700 x g for 10 min.

8 . Using clean disposable transfer pipet each time, remove the lower (CHC13) layer .
9. Repeat steps 6and 8.
10. Transfer the top layer into 1 ml disposable cuvet (do not take the lower layer).
1 1 . Read absorbance at 490 run against the blank.
12. Construct a standard curve get the linear regression equation.

0.12 -

E
C

•
C

.D.
.D.

·0.1

o.os

t

1

y = 0.0052x + 0.001 6
R2 = 0.998

0.00 j
0 .0
4

0 . 02
0

I
0

5

10

15

20

Calf Thymus DNA. µg

DNA Standard Curve

Calculation : µg DNA = Absorbance/Slope x D .F.
Reference: Ceriotti, G. (1 952) A microchemical determination ofDNA. J. Biol. Chem.
1 98:297-303 .
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APPPENDIX 5

Protein Determination (Lowry' s Method)

Reagents

1 . 2 % (w/v) sodium carbonate (N�C03) in 0. 1 N sodium hydroxide (NaOH).
Dissolve 6 g N�C03 in O. IN NaOH and mark-up to 300 ml with DDW.
2. O. IN NaOH.
Dissolve 2g NaOH in 450 ml DDW and mark-up to 500 ml volume.
3 . 1% (w/v) cupric sulfate (CuS04.5H20).
Dissolve 0.5g CuS04.5H20 in DDW and bring up to 50 ml volume.
4. 2% Sodium potassium tartarate (NAKC4H406.4H20).
Dissolve lg NAKC4H406 .4H20 in DDW and bring up to 50 ml volume.
5. Diluted Folin reagent.
Dilute Folin & Ciocalteu's phenol reagent 1 : 1 (v/v) with DOW and store in an amber
bottle at 4 °C.
6. Alkaline copper reagent.
Add 0.5 ml of2% NAKC4H406.4H20 and 1% CuS04 .5H20 solutions to 50 ml of2%
N�C03 in 0. 1 N sodium hydroxide solution (enough for 25 samples). Mix solutions
thoroughly to avoid precipitation of Cu(OH) 2 . Prepare enough just prior to assay
daily.

120
7. 100/o and 0.5 mg/ml bovine serum albumin (BSA).
Dissolve I Og of crystalline BSA in I 00 ml of saline. A working satndard is made by
diluting the 100/o BSA with DDW to give 0.5 mg/ml BSA exactly. Store at less than
0 ° c.

Procedure

1 . Set the protein standards and sample tubes as shown below:
Tube

0.5 mg/ml BSA

DDW

Alk. c11iso..

Folin Reagent

µg PRO

Blank (2 tubes)

0 µl

800 ul

2 ml

0.2 ml

0

SI

15

785

2

0.2

7

S2

30

770

2

0.2

15

S3

60

740

2

0.2

30

S4

90

710

2

0.2

45

S5

120

680

2

0.2

60

S6

1 50

650

2

0.2

75

Sample

20-50

750-780

2

0.2

?

2. Add BSA standards or sample and DDW. Mix.
3 . Add 2.0 ml alkaline Cu2S04 solution. Mix. Stand at room temperature for 1 5 min.
4. Add 0.2 ml diluted Folin reagent. Mix immediately and thoroughly.
5. Stand for 30 min at room temperature.
6. Read absorbance at 750 nm against blank.
7. Plot the regression curve,, and get the linear regression equation.
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1
0.9
0.8

E

C:

0

or
�
�

y = 0.01 5x + 1 E-05
R2 = 0.998

0.7
0.6
0.5
0.4
0.3
0.2
0.1
0

0

10

20

30

40

BSA, mg

Protein Standard Curve

Calculation:
µg Protein = Absorbance/Slope x Dilution Factor.

50

60
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APPEND1X 6

Glutathione S-Transferase Assay of Rat Hepatocytes
Principle
Glutathione S-Transferase (GST) catalyzes the conjugation of glutathione (GSH) with l
chloro-2,4, dinitrobenzene (CDNB) which can be monitored spectrophotometrically at
340 run. (Caution: CDNB is very toxic. Avoid skin contact and inhalation. Prepare
under the hood).
Reagents
1 . O. l M sodium-phosphate buffer, pH 6.5 containing 1 mM EDTA
2.84g NaJIP04 + 0.0584g EDTA in 1 80 ml DDW. Adjust pH to 6.5. Make-up to
200 ml with DOW. Store at -4 ° C.
2. 20 mM GSH in DOW.
0.061 5g GSH dissolve in IO ml DOW. Store at -20 ° C. Stable for about 1 week.
3 . 20 mM CDNB in 95% ethanol.
0.0405g CDNB dissolve in 10 ml of 95% EtOH. Store at 4 ° C.
4. Hank's buffer.
(or any other buffer that was used to suspend the cells)
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Method
Cytosol preparationfrom hepatocyte incubation mixture
1 . Prepare supernatant (SN) fraction from the incubation mixture immediately at the end
of incubation, or after thawing the hepatocytes at -80 °C. All subsequent steps are
done at 4 °C.
2. Centrifuge 0.5 ml of incubation mixture (about 2 x 1 06 cells/ml) at 500 x g for IO min.
Remove supernatant.
3 . Wash and suspend pellet with 0.5 ml Hank's Buffer (HB). Centrifuge and remove
supernatant.
4. Resuspend cells with 0.3 ml HB. Homogenize cell with a pellet pestle for 20 -30 sec.
3. Transfer homogenized cells into a thick-wall Nalgene® ultratube (13 x 5 1 mm).
4. Centrifuge homogenate at 9,000 x g for 1 5 min in a swinging bucket.
5. Transfer SN to a new ultratube, and centrifuge at 100,000 x g for 60 min.
6. Collect the SN (cytosol) and determine protein content by Lowry method
(APPENDIX) using BSA as standard.
(Cytosol could be stored at -80 ° C, but it must be centrifuged at 14000 rpm for 20
min after thawing)
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Assay

O. IM sodium-phosphate buffer

Control

Sample

8 50-89 5 µl

8 50-89 5 µl
I

50 µI

20 mM GSH in DDW

50 µl

20 mM CDNB

50 µI

Hank's Buffer

5- 50 µI

--

--

5- 50 µI

I ml

I ml

(Mix)

Cell cytoso1
Total

50 µl

1 . Prewarm the reagents and cytosol at 30 °C for 5- 1 0 min. or keep them at room
temperature ( 2 5 °C)
2. To two I-ml quartz cuvettte add the buffer, GSH, and CDNB, and for the Control
cuvette add Hank's buffer.
3 . Cap the cuvette with parafilm and mix the reaction mixture by inverting the cuvette 2-3
times.
4. Measure spontaneous reaction by monitoring the rate of absorbance (A) at 3 40 nm
(UV) for 3 min at 30 °C in a Hitachi U- 2000 spectophometer with UV and visible light
on.
5. Cap the cuvette with parafilm and mix the reaction mixture by inverting the cuvette 2-3
times.
6. Monitor and plot the increased in A rate for 3 min.
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Calculation
Specific activity
(µmoVmg protein/min)

=
=

fl. A

flA * V
E * :MP
AA * 1
9. 6 * :MP

= Rate of A change with enzyme - Rate of A change without enzyme (per min at
3 40 run)

V
E

= Volume of reaction mixture = 1 ml
= Extinction coefficient ofCDNB = 9. 6 mM-1 cm-1

:MP = mg of cytosolic protein

Definition:
Specific activity of GST is defined as the amount of the enzyme catalyzes the formation of
one unit or 1 µmol of 2, 4-dinitrophenylglutathione per min at 30 °C using 1 mM ofGSH
and CDNB per mg of protein.

Reference:
Habig et al. (1974) J Biol Chem 2 49:7130-713 9 as described by Warholm et al. (1 985)
Methods in Enzymology 113: 499-507.
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APPENDIX 7

Total Glutathione Assay in Hepatocytes

Principal

I)

2GSH + DTNB - GSSG + 2TNB

2)

GSSG + NADPH + H+

-*

2GSH + NADP+

*GSSH Reductase

GSH is oxidised non-enzymatically with DTNB to produce GSSG and 2TNB. GSSG is
then reduced to GSH enzymatically by GSSH reductase and NADPH. Total GSH is
calculated by the rate of color change of DTNB at 4 12 run for 3-6* min minus the rate of
reduction of DTNB in absence ofGSH or GSSH (blank). The rate ofTNB formation is
proportional to the total amount of GSH and GSSH. The rates are also monitored in
known amount of GSH solutions (standards) to plot the caliberation curve. ·
(*3 min monitoring of the rate of change is sufficient to get the linear portion of the
curve.)

Reagents (for about 100 assays)
1. 100 ml of 10 mM HCI.
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2. 10 ml of 10 % 5-sulfosalicyclic acid.
3. 143 mM sodium phosphate and 6.3 mM EDTA (stock buffer).
Mix 5.077g Na2HPO and 0.59 g EDTA-N3.i.2H20, flask and make-up to 250 ml with
DOW; final pH 7.5. Keep at room temperature or at 4 °C.
4. 0.3 mM NADPH buffer
26.6 mg NADPH tetrasodium salt in 100 ml of stock buffer. Prepare daily and keep at
4 ° C.
5. 266 U/ml GSSH reductase Type III (Bakers yeast).
Dilute yeast enzyme to get 266 U/ml with stock buffer. Keep at 4 °C; stable for 2
weeks.
6. 6 mM 5,5'-dithiobis-(2-nitrobenzoic acid)(DTNB) in stock buffer.
23.8 mg DTNB in I O ml stock buffer. Store at 4 °C; stable for 2 weeks.
7. 20 mM GSH Standard solution (stock standard solution).
Dissolve 6 1.4 mg GSH in 10 ml DOW. Store frozen; stable for 1 weeks.
Dilute stock standard solution with 5-sulfosalicylic acid to give 0.5, 1, 2, 3, and 4 nmol
of GSH. Prepare daily.

Hepatocyte or Blood Sample Preparations
1. Hepatocyte or whole blood sample (20 µl) is added to 100 µl of 1 O mM HCL in a 400
µl or 1. 5 ml microcentrifuge tube.
2. Lyse cell by freezing in liquid nitrogen or dry-ice acetone bath, and thaw.
3. Repeat Step 2 for 3 more times.
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4. Centrifuge in a Beckman microfuge at 10,000 g for 5 min.
5. Transfer 100 µI of the supernatant into a new microcentrifuge tube.
6. Add 50 µI of 10% 5-sulfosalicylic acid and mix to deproteinized the supernatant.
7. Centrifuge in a Beckman microfuge at 10,000 g for 5 min.
8. Up to 25 µI of the protein-free supernatant can be used for assay.

Assay

NADPH buffer
DTNB
DOW

I

I

Reference/Blank

Standard/Sample

700 µI

700 µI

100 µI

100 µI

200 µI

175 µI

--

25 µI

5-10 µI

5-10 µI

(Cap with para.film, mix, and
warm at 30 °Cfor 5 min)

Protein-free sample
(Cap, mix, and zero the Abs)

GSSG reductase
Cap, mix, zero Abs., and read
change in absorbance at 412
run for 3 min.

1. Add the NADPH, DBNB, and DOW into two 1.5 microcentrifuge tubes.
2. Vortex and incubate at 3 7 ° C for 3 min.
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3 . Add 25 µl sample (or blank and standards) to sample cuvet, and mix.
4. Add GSSH reductase to both reference and sample cuvets, and mix gently.
5. Transfer the reaction mixtures into 1.0 ml quartz cuvets.
6. Zero absorbance, and start monitoring change in absorbances for 3 min.
7. Run the assay for GSH standards containing 0, 0.5, 1 , 2, 3, and 4 nmol of GSH
equivalent.
8. Plot rate of absorbance change against GSH equivalent.
9. The amount of total glutathione in sample is calculated from the regression equation
obtained from standard curve graph.
(For other samples, other extraction procedures are outlined by Griffith ( 1 985) and
Anderson ( 1 985). Use the equations in Griffith ( 1 985) to calculate for blood, plasma, and
tissues gl utathione contents)

References

1. Griffith ( 1 985) Methods in Enzymology VIII: 521 -529.
2. Anderson ( 1 985) Methods in Enzymology 1 1 3: 548-555.
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APPEND1X 8

Isolation of Microsomes from Rat Liver

Method
1 . Anesthetize rat with metofane in a jar.
2. Perfuse rat with about 1 00 ml ice-cold physiological saline.
3. Add 20 ml of 0. 1 54 M KCl containing 0.0 1 M KH2P04 (pH 7.4) to 4 g liver (25%
w/v), and homogenize(6 complete strokes) in a Teflon-glass homogenizer.
4. Centrifuge homogenate at 1 0,000 x g for 10 min at 4 °C.
5. Transfer supernatant (SN) into clean centrifuge tubes and centrifuge at 105,000 x g for
60 min at 4 °C.
6. Collect the SN (cytosol) into new tubes.
7. Resuspend microsomal pellet in 4 ml ( 1 ml/g tissue) of glycerol-phosphate buffer ( 1 : 1,
glycerol:0. 1 5M KH2P04, pH7.8).
8. Determine protein content by the method ofLowry et al. (195 1)
9. Store at -80 °C .

Reference
Kato, R. ( 1966) P450 and microsomal oxidation of drugs. J. Biochem. 59: 574-579.
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APPEND1X 9

Binding of AFB 1 to Exogenous DNA in a Microsomal System

Method
1 . Triplicate samples are prepared as follows:

CONTROL

1.2 mM L-CNE

0.5 M Phosphate Buffer

200 µI

200 µI

lOO M NADPH

20 µl

20 µI

[3H]AFB 1 , 2 nmoV20 ml
DMSO

20 µ1

20 µ1

Microsomes, 1 mg protein
equivalent

200 µI

200 µI

4 mg/ml Calf Thymus DNA

25 µI

50 µl

1 0 mM L-CNE, pH 7.0

0 µI

120 µI

DDW

535 µl

4 1 5 µl

TOTAL

1000 µI

1000 µI

..

I

2. Incubate the incubation mixtures at 37 °C for 30 min.
3. Add O .245 ml 5M NaCl to produce a mixture containing IM NaCl, 2 ml of
chloroform:isoamyl alcohol (24: 1 ; v/v), and 0.9 mg calf thymus DNA (0.225 ml of
4 mg/ml DNA) as carrier.
4. Shake the tubes for 1 0 min, and centrifuge at 10,000 x g for 10 min.
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5. Transfer an the top layer (DNA fraction) to new tubes, add 2 m1 ch1oroform:isoamy1

alcohoi shake for 1 0 min., and centrifuge at 10,000 x g for 10 min.
6. Transfer the top layer to new tubes.
7. Add equal vol. of 95% ethanol to precipitate DNA. Vortex. Centrifuge at 1 0,000 x g
for 1 0 min. Remove SN.
8. Dissolve DNA in 1 ml of O. lM NaCl (pH 7.0).
9. Determine DNA content by Ceriotti (1 952) (APPENDIX 4).
10. Transfer 200 ul ofDNA solution into scintillation vials, add 5 ml scintillation fluid,
and DPM for 10 min.

References
I . Allemeh, A., Saxena, M., & Raj, H.G. (1988) Differential effects ofbutylated
hydroxyanisole on metabolism of aflatoxin B 1 in vitro by liver. and lung microsomes.
Cancer Lett. 40:49-57.
2. Hasler, J.A, Dube, N., Nyathi, C.B., Furmann, H., & Sallrnann, H.P. (1 994) The
influence of dietary fat on hepatic bioactivation of aflatoxin B 1 in rats. Res. Commun.
Chem. Patho1. Pharmacol. 83:279-287.
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